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ABSTRACT 
 
INTRODUCTION: Glycogen synthase kinase-3 (GSK-3) is a serine-threonine protein 
kinase that was first discovered as a regulator of glycogen synthase thus playing a 
role in glycogen synthesis (Embi et al. 1980). GSK-3 has also been shown to down 
regulate the expression of SERCA-2a (a calcium ATPase pump) thus playing a role 
in myocardial contractility (Michael et al. 2004). However, SERCA-2a activity is 
regulated by phospholamban (PLM) and sarcolipin (SLN) (Asahi et al. 2003). GSK-3 
is constitutively active in cells and can be acutely inactivated by insulin through 
phosphorylation by PKB/Akt. However, GSK-3 is known to phosphorylate and inhibit 
IRS-1 protein, thus disrupting insulin signaling (Eldar-Finkelman et al. 1996). In 
addition, abnormally high activities of GSK-3 protein has been implicated in several 
pathological disorders which include type 2 diabetes, neuron degenerative and 
affective disorders (Eldar-Finkelman et al 2009). This led to the development of new 
generations of inhibitors with specific clinical implications to treat these diseases 
(Martinez 2008). GSK-3 inhibition has been shown to improve insulin and blood 
glucose levels and to be cardioprotective during ischemia/reperfusion (Nikoulina et 
al. 2002; Kumar et al. 2007). 
 
AIMS: To determine whether myocardial GSK-3 protein and its substrate proteins 
are dysregulated in obesity and insulin resistance, and whether a specific GSK-3 
inhibitor can prevent or reverse the cardiovascular pathology found in obese and 
insulin resistant animals. 
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OBJECTIVES: To correlate the alterations in expression and activation of GSK-3 
protein in a well characterised rat model of obesity coupled to insulin resistance with: 
i) myocardial contractile dysfunction and an inability of hearts to withstand 
ischemia/reperfusion, ii) the activation and expression of phospholamban and 
SERCA-2a in the sarcoplasmic reticulum, iii) the activation of intermediates (IRS-1, 
IRS-2 and PKB/Akt) that lie upstream in the activation pathway of GSK-3 and iv) to 
determine the effects of inhibition of GSK-3 on the abovementioned parameters. 
 
METHODS: Age and weight matched male Wistar rats (controls and diet induced 
obese (DIO) animals) were used in the present study. Controls were fed normal rat 
chow, while DIOs were fed a rat chow diet supplemented with sucrose and 
condensed milk, for 8 or 16 weeks. Half of each group of animals were treated with 
the GSK-3 inhibitor for 4 weeks (from 12 to 16 weeks). After the feeding and 
treatment period, animals were weighed, sacrificed, hearts removed and freeze 
clamped immediately or perfused with Krebs-Henseleit buffer and subjected to low 
flow ischemia (25 min) followed by 30 min reperfusion. Biometric (body weight, 
intraperitoneal fat, ventricular weight and tibia length) and biochemical (fasting blood 
glucose and insulin levels) parameters were determined. Expression of GSK-3, 
PKB/Akt, IRS-1, IRS-2, SERCA-2a and Phospholamban were determined by 
Western blotting. Ca2+ ATPase activity was determined spectrophotometrically. 
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RESULTS: At both 8 and 16 weeks DIO animals were significantly bigger than 
control animals and this was associated with increased intraperitoneal fat in DIOs. In 
DIO animals: IRS-1 was downregulated at 8 weeks and both IRS-1 and IRS-2 as 
well as PKB/Akt at 16 weeks. There was an increased tendency of GSK-3 
expression at both 8 and 16 weeks in DIO animals while SERCA-2a was severely 
downregulated from 8 weeks onwards and associated with lower Ca2+-ATPase 
activity. PLM expression was upregulated but its phosphorylation was attenuated. At 
16 weeks, baseline heart rate (225 vs 275 in control, P<0.0001, n=6) and rate 
pressure product (21000 vs 30000 in control, P=0.019, n=6) were significantly lower 
in hearts from DIO animals. Functional recovery was unchanged but the time to 
ischemic contracture development was increased (11.6±0.4 control vs 16.2±0.5 min 
DIO, P<0.01, n=6). Treatment had no effect on total GSK-3 expression. However, 
GSK-3 phosphorylation was significantly increased in treated controls, while there 
was no significant difference in DIO animals. However, there was a tendency for an 
increased GSK-3 phosphorylation in treated DIO animals. GSK-3 inhibitor, improved 
hypertrophy in DIO animals, while it led to its development in control animals. GSK-3 
inhibitor improved IRS-2 expression in both control and DIO animals while it had no 
effect on IRS-1 and SERCA-2a expression and activity. However, GSK-3 inhibition 
increased PKB/Akt and phospholamban phosphorylation in DIO animals. 
 
CONCLUSION: These findings show that high calorie diet as well as imbalance 
between energy intake and expenditure lead to the development of obesity and 
insulin resistance in male Wistar rats. We showed that GSK-3 and its substrate 
proteins are dysregulated in obesity and insulin resistance. The reduced SERCA-2a 
expression at baseline may have a negative impact on cardiac function. By treating 
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the animals with GSK-3 inhibitor, we showed that GSK-3 protein may not be 
responsible for changes seen at baseline. The decreased IRS-1 and SERCA-2a 
expression may have been caused by a different mechanism other than the actions 
of GSK-3. However, according to this study, GSK-3 may play a role in regulation of 
IRS-2 expression but not in IRS-1. Increased PKB/Akt phosphorylation may 
contribute to the GSK-3 inhibition. In addition, GSK-3 inhibition may reverse cardiac 
hypertrophy in DIO animals, thus acting as a negative regulator of hypertrophy. 
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OPSOMMING 
 
Inleiding: Glikogeen sintase kinase-3 (GSK-3), ‗n serien/threonien proteïen kinase, 
is oorspronklik ontdek as ‗n rolspeler in glikogeen sintese, aangesien dit ‗n 
reguleerder van glikogeen sintase is (Embi et al.1980). Intussen is dit ook bevind dat 
GSK-3 die uitdrukking van SERCA-2a (‗n kalsium ATPase pomp) kan afreguleer en 
dus sodoende ‗n rol speel in miokardiale kontraktiliteit (Michael et al. 2004). Die 
aktiwiteit van SERCA-2a kan egter ook gereguleer word deur fosfolamban (PLM) en 
sarkolipin (Asahi et al. 2003). GSK-3 is deurgaans aktief, maar kan tydelik 
geïnaktiveer word onder kondisies van insulien stimulasie deur PKB/Akt 
gemedieerde fosforilering. Aan die ander kant is dit bekend dat GSK-3 die IRS-1 
proteïen kan fosforileer om dus sodoende insulien sein-transduksie af te reguleer 
(Eldar-Finkelman et al. 1996). Daarmee saam is abnormaal hoë vlakke van GSK-3 
aktiwiteit geassosieer met verskeie patologiese versteurings, insluitend tipe 2 
diabetes, neuron degeneratiewe en affektiewe versteurings (Eldar-Finkelman et al. 
2009). Daar is dus nuwe generasies GSK-3 inhibitore ontwikkel met die kliniese 
potensiaal om hierdie patologieë te behandel (Martinez 2008). Dit is al bevind dat 
GSK-3 inhibisie geassosieer kan word met beide die normalisering van plasma 
insulien- en glukose vlakke, asook kardiobeskerming in die konteks van 
iskemie/herperfusie (Nikoulina et al. 2002; Kumar et al. 2007). 
 
Doelwitte: Om te bepaal of GSK-3 proteïen en sy substraat proteïene gedisreguleer 
is onder kondisies van obesiteit en insulien weerstandigheid, asook om vas te stel of 
‗n spesifieke GSK-3 inhibitor die kardiovaskulêre patologie wat gevind word in obese 
en insulien weerstandige diere kan verhoed of omkeer. 
vii 
 
Mikpunte: Om veranderinge in uitdrukking en aktiwiteit van GSK-3 proteïen in ‗n 
goed gekarakteriseerde rotmodel van obesiteit, gekoppel aan insulien 
weerstandigheid, te korreleer met die volgende: i) miokardiale kontraktiele disfunksie 
en onvermoë om kardiale iskemie/herperfusie besering te weerstaan, ii) aktivering 
en uitdrukking van PLM en SERCA-2a in die sarkoplasmiese retikulum, iii) die 
aktivering van intermediêres wat proksimaal geleë is in die 
insulienseintransduksiepad van GSK-3 (IRS-1, IRS-2 en PKB/Akt) en iv) om die 
effek van behandeling met ‗n spesifieke inhibitor van GSK-3 op die bogenoemde 
punte te bepaal.  
 
Metodes: Ouderdoms- en gewigsgepaarde manlike Wistar rotte (kontrole en dieet 
geïnduseerde obees (DIO) diere) is in die studie gebruik. Kontrole diere was normale 
rotkos gevoer, terwyl die DIO diere op ‗n dieet van rotkos aangevul met sukrose en 
kondensmelk geplaas is vir ‗n periode van 8 of 16 weke. Helfte van die diere van 
elke groep is behandel met die GSK-3 inhibitor vir 4 weke (vanaf week 12 tot 16). Na 
afloop van die voer- en behandelingsperiode is die diere geweeg, doodgemaak en 
die harte verwyder om dan of onmiddelik gevriesklamp te word, of retrograad 
geperfuseer te word met Krebs-Hensleit buffer. Ex vivo geperfuseerde harte is dan 
blootgestel aan 25 minute lae vloei iskemie gevolg deur 30 minute herperfusie. 
Biometriese (liggaamsgewig, intraperitoneale vet, ventrikulêre gewig en tibia lengte) 
en biochemiese (vastende bloedglukose en -insulien vlakke) parameters is telkens 
bepaal. Western klad tegnieke is gebruik om die uitdrukking en fosforilering van 
GSK-3, PKB/Akt, IRS-1, IRS-2, SERCA-2a en PLM te bepaal. Ca2+-ATPase 
aktiwiteit is spektrofotometries bepaal. 
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Resultate: Na beide 8 en 16 weke was die DIO diere beduidend swaarder as die 
kontrole diere. Hierdie gewigstoename was geassosieer met meer intraperitoneale 
vet in die DIO diere. Verder, in die DIO diere was IRS-1 afgereguleer na 8 weke, 
terwyl beide IRS-1 en IRS-2 asook PKB/Akt afgereguleer was na 16 weke. GSK-3 
uitdrukking het ‗n neiging getoon om toe te neem na beide 8 en 16 weke in die DIO 
diere, terwyl SERCA-2a beduidend afgereguleer was reeds vanaf 8 weke, 
geassosieer met laer Ca2+-ATPase aktiwiteit. PLM uitdrukking het toegeneem en die 
fosforilering daarvan was verlaag. Op 16 weke was die basale harttempo (225 vs 
275 in die kontrole groep, P<0.0001, n=6) en tempo druk produk (21000 vs 30000 in 
die kontrole groep, P=0.019, n=6) betekenisvol laer in die DIO diere. Funksionele 
herstel het onveranderd gebly, alhoewel die tyd tot iskemiese kontraktuur 
toegeneem het in die DIO groep (kontrole: 11.6±0.4 min vs DIO: 16.2±0.5 min, 
P<0.01, n=6). Toediening van die inhibitor het geen effek op totale GSK-3 
uitdrukking gehad nie. Fosforilering van GSK-3 was egter wel beduidend verhoog in 
die behandelde kontrole diere, terwyl daar geen verskille in die DIO groep was nie. 
Die fosforilering van GSK-3 het wel geneig na ‗n toename in die behandelde DIO 
diere. Die GSK-3 inhibitor het kontrasterende effekte op hipertrofie gehad: dit het dit 
omgekeer in die DIO groep, maar veroorsaak in die kontrole diere. Daarmee saam 
het die inhibitor die uitdrukking van IRS-2 in beide DIO en kontrole diere gestimuleer, 
maar geen effek op IRS-1 en SERCA-2a uitdrukking en aktiwiteit gehad nie. GSK-3 
inhibisie het wel PKB/Akt en PLM fosforilering in die DIO diere verhoog. 
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Gevolgtrekking: Hierdie bevindinge toon dat ‗n hoë kalorie dieet, tesame met ‗n 
wanbalans tussen energie inname en verbruiking, lei tot die ontwikkeling van 
obesiteit en insulien weerstand in manlike Wistar rotte. Die studie het ook getoon dat 
GSK-3 en sy substraat proteïene wel gedisreguleer is in obesiteit en insulien 
weerstandigheid. Die verlaagde basale uitdrukking van SERCA-2a mag dalk ‗n 
negatiewe impak hê op kardiale funksie. Behandeling van die diere met ‗n GSK-3 
inhibitor het getoon dat GSK-3 moontlik nie verantwoordelik is vir die basislyn 
veranderinge nie. Die afname in IRS-1 en SERCA-2a uitdrukking kan moontlik 
toegeskryf word aan ander meganismes buiten die effekte van GSK-3. Hierdie studie 
toon wel dat GSK-3 moontlik ‗n rol speel in die regulering van die uitdrukking van 
IRS-2, maar nie IRS-1 nie. Verhoogde PKB/Akt fosforilering mag dalk bydra tot die 
inhibisie van GSK-3. Daarmee saam blyk dit dat GSK-3 inhibisie hipertrofie kan 
omkeer in DIO diere, om dan sodoende op te tree as ‗n negatiewe reguleerder van 
hipertrofie, maar in normale kontrole diere, hipertrofie in die hand werk. 
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CHAPTER 1 
LITERATURE REVIEW 
 
1.1 Definition of Obesity 
Obesity is defined as a state or condition where body fat content is increased to an 
extent that poses a risk to develop chronic diseases such as cardiovascular, 
pulmonary (sleep apnea), metabolic (diabetes, insulin resistance and dyslipidaemia), 
osteoarticular diseases, common forms of cancer (cervical, uterus, breast, ovarian 
and kidney) and other serious psychological illnesses (Bray and Bourchard 2004; 
Grundy 2004; Sodjinou et al. 2008).  
 
The adipose mass may be distributed around the body and these individuals are said 
to be apple shaped, or the fat mass may be distributed in certain areas of the body 
such as abdomen, thighs and hips resulting in a pear-shaped body (Jackson et al. 
2003; Wells et al. 2008). Body fat mass exceeds its normal content, partly as a result 
of unhealthy eating habits and sedentary lifestyle (Grundy 2004; Hicks 2006). In 
adults, obesity is mostly determined by calculating the body mass index (BMI), which 
is weight in kilograms divided by height in square meters (kg/m2). According to the 
World Health Organization (WHO) criteria, individuals whose BMI is between 18.5 
and 25 kg/m2 are classified as normal, those between 25 and 30 kg/m2 as 
overweight, and above 30 kg/m2 as obese (National Institute of Health (NIH) 1998; 
Hicks 2006). 
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1.1.1 Prevalence of obesity 
Obesity is significantly and increasingly becoming a major public health problem in 
both affluent and developing countries with 33% of adults reported to be overweight 
or obese in 2005 (Medeiros et al. 2003; Kosti and Panagiotakos 2006; Kelly et al. 
2008b). It is further estimated that by 2030, 57.8% of the world‘s adult population 
would be either overweight or obese (Kelly et al. 2008b). Higher prevalence of 
overweight and obesity have been reported in developed countries in comparison to 
developing ones (35.2% vs 19.6% overweight adult and 20.3% vs 6.7% of obese 
people) (NIH 1998; Kelly et al. 2008b). The lower prevalence observed in developing 
countries does not necessarily mean that less people are affected, but is rather more 
due to larger populations in these countries (Kelly et al. 2008b). 
 
However, in the past decade, the prevalence of obesity has tripled in developing 
countries, particularly those that have adopted a Westernized lifestyle (i.e., 
overconsumption of energy-dense food and increased physical inactivity) (Jackson 
et al. 2003; Kelly et al. 2008a). This has been attributed to, among other factors, 
growth in population size, urbanization, changes in lifestyle that include consumption 
of energy-dense food and physical inactivity (Hill and Peters 1998; Grundy 2004; 
Hicks 2006). Today, obesity in countries such as Brazil, China and those in Sub-
Saharan Africa including South Africa, is increasing rapidly and exceeding levels 
reported in affluent countries (Kelly et al. 2008a). According to the WHO report 
published in 2005, the prevalence of overweight or obesity in America was 26.6% in 
men and 32.2% in women (Hicks et al 2006; Kelly et al. 2008b). In 2002, the obesity 
epidemic in South Africa was as high as 29% in men and 56% in women (Puoane et 
al. 2002; Kelly et al. 2008b). 
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1.2 Definition of Insulin resistance (IR) 
Insulin resistance is a pathological state in which cells (muscle, adipose tissue and 
liver) fail to respond to the normal concentrations of insulin (review by Mlinar et al. 
2007; Saltiel 2001). Insulin is a hormone produced by pancreatic beta cells that is 
responsible for lowering blood glucose by promoting cellular uptake, for either 
glycogen storage or cellular utility (Lomedico et al. 1979; Toriumi and Imai 2002; 
DeFronzo and Ferranini 2001; review by Mlinar et al. 2007). IR results in an inability 
of insulin to provide normal glucose and lipid homeostasis (Wang et al. 2004; Eckel 
et al. 2005). Insulin resistant individuals need higher insulin levels than normal to 
control blood glucose levels and as a result, the pancreas produces more to keep up 
with this increased demand (Eckel et al. 2005; National Diabetes Information 
Clearinghouse (NDIC) 2008). Under this condition the pancreas eventually fails to 
meet the insulin demands of the body, resulting in increased plasma glucose levels 
to an extent where diabetes develops (Weir and Bonner-Weir 2004; NDIC 2008).  
 
Insulin resistance may be caused by excess weight gain (obesity) and it has also 
been reported that there are certain genes that make people susceptible to this 
condition (Reaven 1988; Haffner et al. 1997). These individuals usually have, in 
addition to insulin resistance, high blood pressure, excess weight around the waist 
(central obesity) and high levels of unwanted triglycerides (lipids) and cholesterol in 
the blood, leading to the development of chronic diseases such as type 2 diabetes 
and cardiovascular diseases (Grundy et al. 2004). Insulin resistance also results in 
alteration of the insulin signaling pathway (section 1.7) (review by Frojdo et al. 2009). 
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1.3 Definition of Diabetes 
Diabetes is a condition whereby the blood sugar (glucose) is increased above 
normal levels (8 mmol/L in the fasting state), due to an inability of the body to utilize 
it sufficiently to produce energy (NDIC 2008; review by Frojdo et al. 2009). This state 
develops prior to an inability of the body to produce enough insulin, which is 
responsible for the intake of energy from various food sources by the cells (NDIC 
2008; review by Frojdo et al. 2009). As mentioned above, insulin is also responsible 
for the conversion of excess plasma glucose into its storage form glycogen (Toriumi 
and Imai 2002; DeFronzo and Ferranini 2001; NDIC 2008). Glycogen is then stored 
in adipose tissues, muscles and liver for later use (Grundleger and Thenen 1982; 
Henry et al. 1995).  
 
There are three types of diabetes that exist in humans, type I, II and gestational 
diabetes (Alberti and Zimmet 1998; Chou 2004). Type I diabetes is an autoimmune 
disease, that leads to the failure of the body to produce adequate concentrations of 
insulin, because of a lack of pancreatic beta cells (Alberti and Zimmet 1998; Hunt 
and Garvy 1998; Chou 2004). Type I diabetes affects children, teenagers and young 
adults and is known as juvenile or insulin dependent diabetes (Alberti and Zimmet 
1998; NDIC 2008). Individuals with type I diabetes survive by regular insulin 
injections (Alberti and Zimmet 1998; NDIC 2008). In type II diabetes, also known as 
adult onset or noninsulin-dependent diabetes, pancreatic beta cells produce enough 
insulin but the peripheral insulin sensitive cells fail to respond to normal levels of 
insulin, a state known as insulin resistance (section 1.2) (Alberti and Zimmet 1998; 
Herinksen and Dokken 2006; NDIC 2008). Gestational diabetes affects pregnant 
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women but it disappears after birth and it is normally caused by the shortage of 
insulin and hormones of pregnancy (NDIC 2008). 
 
Altered expression, activity and function of all transporters involved in calcium 
regulation and excitation- contraction coupling (Sarcoplasmic/endoplasmic reticulum 
Calcium (Ca2+) ATPase (SERCA), Na+/ Ca2+-exchanger (NCX), ryanodine receptors 
(RyR) and plasmalemmal Ca2+-ATPase (PMCA)) have been reported in both type I 
and II diabetic rodent models (Golfman et al. 1998; Vetter et al. 2002). Thus, 
diabetes is strongly associated with the development of cardiovascular complications 
such as diabetic cardiomyopathy (Fonarow and Srikanthan 2006). These 
cardiovascular complications are the leading causes of morbidity and mortality in 
diabetic patients (Vetter et al. 2002; Cesario et.al. 2006). 
 
1.4 Definition of Cardiomyopathy 
Cardiomyopathy literally means cardiac muscle pathology (Kasper et al. 2005). It is 
defined as a chronic disease where the heart muscle (myocardium) is weakening 
prior to inflammation leading to deterioration of its function (Kasper et al. 2005; 
Thiene et al. 2008). It also refers to a heterogeneous group of diseases of the 
myocardium associated with the mechanical and electrical dysfunction that usually 
exhibit inappropriate ventricular hypertrophy or dilation (Maron and Salberg 2001; 
Barry et al. 2007; Hypertrophic Cardiomyopathy Association (HCA) 2009). There are 
multiple causes of this condition which include among others viral infections (Kasper 
et al. 2005; Elliott et al. 2008; review by Wexler et al. 2009; HCA 2009). 
Cardiomyopathy is classified as intrinsic (primary) or extrinsic (specific/secondary) 
according to the cause (review by Wexler et al. 2009; HCA 2009). 
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1.4.1 Intrinsic cardiomyopathy 
Intrinsic cardiomyopathy refers to a weakness within the cardiomyocyte that is not 
based on manifested systemic pathophysiological characteristics which means, it 
cannot be linked to a specific cause such as high blood pressure, heart valve 
defects, artery and congenital heart defects (Richardson et al. 1996; Fonarow and 
Srikanthan 2006; review by Wexler et al. 2009). There are four main types of intrinsic 
cardiomyopathy i.e. dilated cardiomyopathy (DCM), hypertrophic cardiomyopathy 
(HCM), restrictive cardiomyopathy (RCM) and arrythmogenic right ventricular 
cardiomyopathy (ARVC) but other types that do not readily fit into any group 
(unclassified cardiomyopathies) have been recognized (Richardson et al. 1996; 
Fuster and Hurst 2004; Thiene et al. 2008). 
 
1.4.1.1 Dilated cardiomyopathy 
It is the most common form and affects about 5 in 100 000 adults and 1 in 200 000 
children (review by Wexler et al. 2009; National heart, lung and blood institute 
(NHLBI) 2009). As the name proclaims, in this condition the cardiac ventricles are 
stretched, therefore enlarged (dilated) allowing more blood to enter (NHLBI 2009; 
Fatkin et al. 2010). Because the heart is weak it cannot pump the blood out as 
normal, leading to abnormal heart rhythms called arrhythmias and heart failure 
(Maron et al. 2006; NHLBI 2009). Also in a dilated heart and arteries, blood moves 
slowly and this may result in clot (thrombus) formation, hampering the blood 
circulation (NHLBI 2009; Fatkin et al. 2010). In adults, dilated cardiomyopathy may 
be caused by coronary artery diseases (CAD) (ischemic cardiomyopathy) and 
hypertension, but it can also be caused by viral myocarditis, valvular disease and 
genetic predisposition (Hunt et al. 2005; NHLBI 2009). In children, dilated 
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cardiomyopathy may be caused by neuromuscular diseases such as Duchenne 
muscular dystrophy, Becker muscular dystrophy and Barth syndrome (Kaski et al. 
2007; NHLBI 2009). 
 
1.4.1.2 Hypertrophic cardiomyopathy 
This is a state where cardiac muscle mass of the left ventricle enlarges and become 
hypertrophic (HCA 2009; review by Boudina and Abel 2010). It is reported that 
enlarged left ventricular (LV) mass is an independent risk factor for heart failure and 
in type 2 diabetes it may occur without an increased arterial blood pressure and may 
also contribute to myocardial compliance reduction (Aneja et al. 2008; HCA 2009). It 
may be caused by 11 mutant genes consisting of more than 500 individual 
transmutations, in which the most common variant involve beta-myosin heavy chain 
and myosin binding protein C (Maron et al. 2003; HCA 2009). 
 
1.4.1.3 Restrictive cardiomyopathy  
In this state the myocardium of the ventricles hardens or become rigid, preventing 
the ventricles from filling and contracting per heart beat (review by Wexler et al. 
2009; NHLBI 2009). Restrictive cardiomyopathy may be caused by infiltrative 
processes (Maron et al. 2006; NHLBI 2009). A rare form of restrictive 
cardiomyopathy known as obliterative cardiomyopathy has been reported, in this 
type the myocardium in the apex of the left and right ventricle thickens and become 
fibrotic thus decreasing the volume within the ventricles (Richardson et al. 1996; 
NHLBI 2009). 
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1.4.1.4 Arrythmogenic right ventricular cardiomyopathy 
Arrythmogenic right ventricular cardiomyopathy is defined as an autosomal dominant 
disorder of the right ventricular muscle (review by Wexler et al. 2009; NHLBI 2009). 
In this condition, the myocardium is replaced by fatty and fibrous tissue mass which 
compromise cardiac function, leading to syncope, ventricular arrhythmias, heart 
failure and sudden death (Hulot et al. 2004; Buja et al. 2008). 
 
1.4.2 Extrinsic (specific) cardiomyopathy 
Extrinsic (specific) cardiomyopathy is attributed to specific causes located outside 
the myocardium, which may be diseases involving other organs and the heart i.e. 
ischemic, valvular, hypertensive, and diabetic cardiomyopathy (Fonarow and 
Srikanthan 2006; NHLBI 2009). 
 
1.4.2.1 Diabetic cardiomyopathy 
Diabetic cardiomyopathy is the term first introduced by Rubler et al in 1972 that refer 
to a clinical condition which develops in patients with diabetes (Fonarow and 
Srinkanthan 2006; Karnik et al. 2007; review by Boudina and Abel 2010). It denotes 
diabetes associated changes in structure of the plasma membrane, mitochondria, 
sarcoplasmic reticulum (SR) and the morphology of the cardiac interstitium (review 
by Adeghate 2004; Karnik et al. 2007; NHLBI 2009). It is also associated with 
changes in the function of the myocardium, resulting in dysfunctional ventricles 
without chronic diseases such as coronary atherosclerosis and hypertension 
(Poornima et al. 2006; Karnik et al. 2007; review by Boudina and Abel 2010). The 
etiology of diabetic cardiomyopathy is very complex, as a result, several factors have 
been implicated in its pathogenesis i.e. variations in cardiac metabolism, decreased 
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vascular sensitivity and abnormal reactivity to various ligands, increased ventricular 
wall stiffness and abnormalities of various ion channels that control ionic 
homeostasis across the cell membrane (Hayat et al. 2004; Cesario et.al. 2006;). 
Diabetic cardiomyopathy may be caused by increased triglycerides and nonesterified 
fatty acids (NEFAs) therefore hyperlipidemia (Poornima et al. 2006; Karnik et al. 
2007) or increased plasma insulin levels above normal followed by the failure of 
pancreatic beta cells to produce insulin. Furthermore, this leads to increased blood 
glucose levels (hyperglycemia), that is known to cause reactive oxygen species and 
reactive nitrogen species release (review by Cai and Kang 2001, Poornima et al. 
2006; Karnik et al. 2007). However, it may be functionally characterized by 
ventricular dilation (dilated cardiomyopathy), myocyte hypertrophy (hypertrophic 
cardiomyopathy), prominent fibrosis and decreased or preserved systolic function 
(Fonarow and Srikanthan 2006; NHLBI 2009). 
 
1.5 Cardiac myocyte 
Heart muscle is a highly organized tissue, composed of several cell types including 
smooth muscle cells, fibroblasts and cardiac myocytes (Zellner et al. 1991; review by 
Walker and Spinale 1999). A cardiac myocyte is the fundamental contractile cell of 
the myocardium that is responsible for force generation (Zellner et al. 1991; review 
by Walker and Spinale 1999). However, transduction of this force into mechanical 
pump performance depends on the interaction between the myocyte and 
extracellular matrix (Robinson et al. 1986; Zellner et al. 1991; review by Walker and 
Spinale 1999). Extracellular matrix ensures proper alignment of the myocyte during 
diastole, coordinates myocyte contraction during systole and also maintains capillary 
patency throughout the cardiac cycle (Buck and Horwitz 1987). 
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The myocyte consists of a basement membrane which forms a boundary between 
the extracellular and intracellular spaces (Timpl 1985; Zellner et al. 1991; review by 
Walker and Spinale 1999). Basement membranes are primarily composed of 
collagen IV, the glycoprotein, laminin, fibronectin, and proteoglycans (Timpl 1985; 
review by Martin and Timpl 1987; Junqueira et al. 1992). The basement membrane 
provides an interface to the collagen matrix of the extracellular space with anchoring 
fibers that attach basal lamina to the underlying collagen (Stanley et al. 1982; 
Junqueira et al 1992). The function of the basement membrane is to provide an initial 
barrier that influences the selective exchange of macromolecules between the 
extracellular space and the myocyte (Stanley et al. 1982; review by Walker and 
Spinale 1999). It also provides an interface for myocyte adhesion and continuity with 
the extracelluar matrix (Paulsson 1992) (figure 1.1). 
 
Figure 1.1: Cardiac myocyte. Shown are the myofibrils, basement membrane, T-
tubules, mitochondrion, terminal cisternae, sarcolemma, sarcomere, z-lines and 
bands (A, H and M) (Taken and edited from: Griffin et al. 2004) 
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1.5.1 Sarcolemma 
Myocytes also contain a specialized structure known as sarcolemma, which is a 
coalescence of the plasma membrane proper and the basement membrane (figure 
1.1) (review by Walker and Spinale 1999). Sarcolemma is composed of a lipid 
bilayer that consists of hydrophilic heads (facing outside) and hydrophobic tails 
(inside), which allows it to interact with both intracellular and extracellular 
environment (Sachse et al. 2008). The hydrophobic core of the sarcolemma leads to 
the impermeability of sarcolemma to charged molecules (review by Walker and 
Spinale 1999). Sarcolemma invaginates into the cytosol forming a transverse tubular 
system (t-system) (Block et al. 1988). 
 
1.5.1.1 Intercalated discs and transverse tubules (T-tubules) 
Sarcolemmal extensions form two specialized regions of the myocyte i.e. the 
intercalated disks and the transverse tubular system (figure 1.1) (Brette and Orchard 
2003). Intercalated disks are specialized cell-cell junctions that serve both as a 
strong mechanical linkage between myocytes and as a path of low resistance that 
allows for rapid conduction of the action potential (Katz 1992). Transverse tubules 
(T-tubules) are sarcolemmal invaginations into the myocytes that form a barrier 
between extracellular and intracellular space (Block et al. 1988). They bring L-type 
Ca2+ channels and the sarcoplasmic reticulum Ca2+ discharge system in close 
proximity (Bers 2002). The fundamental function of the sarcolemma is to provide a 
barrier for diffusion, thus it contains membrane proteins which include receptors, 
pumps and channels which are also important for the contractile process of the 
myocyte (review by Walker and Spinale 1999; Sachse et al. 2008).  
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1.5.1.2 Sarcolemmal pumps and ion channels (Action potential) 
Ion channels are a diverse group of pore forming proteins that transverse the cell 
membrane to allow the selective passage of ions across it (Kass 2005). Ion channels 
and sarcolemmal pumps are the major transducers of intercellular physiologic 
signals in the heart (Cesario et al. 2006; Kass 2005). Sarcolemmal pumps and ion 
channels play an important role in the action potential, a process in which the 
electrical membrane potential of a cell propagates (Carmeleit 2004). The co-
ordination of the action potential depends on several different ion channels within the 
sarcolemma (Carmeliet 2004; Cesario et al. 2006).  
 
As shown in figure 1.2 below, there are four phases of the action potential (phases 0, 
1, 2, 3 and 4) (Wahler 2001b). During the first phase of the action potential i.e. phase 
4 also known as resting membrane potential, the sarcolemma is only permeable to 
K+, therefore it is the K+ equilibrium potential that determines the resting membrane 
potential (about -90 mV) of the myocyte (Barach and Wikswo 1991; Wahler 2001b). 
Phase 4 is maintained primarily by the inward K+ rectifier channel which allows 
diffusion of K+ into the myocyte and is secondarily influenced by the Na+/Ca2+ 
exchanger and the sarcolemmal Ca2+ ATPase (review by Walker and Spinale 1999; 
Faber and Rudy 2000). The Na+/K+ ATPase, which is also a site for digitalis binding, 
generates a net outward current through the extrusion of three Na+ ions for two K+ 
ions (Barach and Wikswo 1991; Faber and Rudy 2000), while the Na+/Ca2+ 
exchanger and the sarcolemmal Ca2+ ATPase provide a basis for Ca2+ extrusion 
from the myocytes (review by Walker and Spinale 1999; Faber and Rudy 2000). The 
Na+/Ca2+ exchanger is a bidirectional channel that allows either ion to be carried 
across the membrane with the amount determined by the concentration gradient on 
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either side of the membrane (Philipson 1990; Faber and Rudy 2000). However, in 
myocytes the Na+/Ca2+ exchanger is the primary system for Ca2+ efflux (Philipson 
1990; Hryshko and Philipson 1997). Maintaining the balance between Ca2+ efflux 
and influx can contribute to the maintenance of the resting membrane potential 
(Philipson 1990; Hryshko and Philipson 1997). 
 
Figure 1.2: Ventricular myocyte action potential. Diagrammatic representation of an 
adult mammalian ventricular myocyte action potential (AP). Four phases of the 
action potential are labelled (0-4). ICa,(calcium current); IK (potassium current) and INa 
(sodium current) (Taken from: Klabunde 1998-2010). 
 
When the membrane potential reaches the predetermined threshold voltage of -70 
mV, Na+ channels (fast) are activated rapidly (<1 ms) and remain active for a 
duration of about 2 to 10 ms (review by Walker and Spinale 1999; Wahler 2001a). 
Na+ channel activation allows Na+ to flow into the cell followed by both electrical and 
chemical concentration gradients (Brown et al. 1981; Faber and Rudy 2000; Franco 
et al. 2006). This triggers other ionic processes responsible for the other phases (1, 
2 and 3) of the action potential (review by Walker and Spinale 1999; Wahler 2001b). 
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Early repolarization is evidenced when rapid inactivation of the Na+ channels and 
slower activation of two outward currents prevail (Ruben 2001; Wahler 2001b; Zaza 
2010). This is then followed by a positive membrane potential, where a Cl- 
concentration gradient and increased membrane permeability to Cl- allows the entry 
of Cl- into the cell (Wahler 2001b; Ruben 2001; Zaza 2010). In addition, a transient 
efflux of K+ through specific channels takes place along with the K+ electrochemical 
gradient (Wahler 2001b; Ruben 2001; Franco et al. 2006). These three events 
contribute to a brief and small repolarization occurring during the phase 1 of the 
action potential (Coraboeuf 1969; review by Walker and Spinale 1999).  
 
When the membrane potential depolarizes to about -40 mV, L-type Ca2+ channels 
open, leading to the influx of Ca2+( Wahler 2001b). Influx of Ca2+ through the L-type 
Ca2+ channels leads to a plateau phase (phase 2) of the action potential which is 
followed by a counter balancing outward K+ current flowing through the K+ rectifier 
(Coraboeuf 1969; Balke and Shorofky 1998; review by Mukherjee and Spinale 
1998). These two channels are normally activated during the upstroke of the action 
potential and reach peak current during the plateau phase (Bers 2002a). Increased 
K+ conductance through the delayed rectifier of the K+ channels results in 
repolarization (phase 3) (Wahler 2001b). Towards the end of the plateau phase, K+ 
channels are activated resulting in K+ ions to flow along the concentration gradient 
(Barach and Wikswo 1991). During this phase all other inward currents such as Na+ 
and Ca2+ are inactivated, therefore making the delayed rectifying K+ current 
responsible for the restoration of the membrane potential to the resting state 
(Mazzanti and DeFelice 1990; Nanasi et al. 1998). 
 
15 
 
1.5.1.3 Contractile apparatus  
The basic unit of contraction in the myocyte is a sarcomere (figure 1.1) which is 
composed of thick and thin filaments and has a resting length of about 1.8-2.4 µm 
(Berne and Levy 1997). The sarcomere also contains the regulatory components of 
the contractile apparatus which are myosin, actin, tropomyosin and troponin protein 
complex, figure 1.3 (Berne et al. 1997). When intracellular Ca2+ concentration is 
increased, myosin, actin, tropomyosin and troponin proteins interact with each other 
resulting in changes in physical and chemical dynamics, leading to the development 
of tension which is accompanied by the hydrolysis of ATP (Williams 1997; Tajsharghi 
2008).  
 
Thick filaments (myosin) are composed of a filamentous tail and a globular head 
region that contains the actin binding site and the catalyzing site for ATPase activity, 
figure 1.3 (Rayment et al. 1993; Hooper et al. 2008). Thin filaments are mainly 
composed of actin which has two isoforms, figure 1.3 (G and F) (Tajsharghi 2008). 
F-actin forms the backbone of the thin filaments while G-actin, which has two myosin 
binding sites, works as a stabilizing protein (Gordon et al. 2000). In the presence of 
ATP, the interaction between the myosin globular head and the G-actin monomer 
results in crossbridge formation and shortening of the sarcomere length (review by 
Walker and Spinale 1999; Craig and Lehman 2001). Also found in the thin filaments 
is the rigid α-helical protein (±40 nm long) molecule known as tropomyosin (Spudich 
et al. 1972; Perry 2001).  
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Figure 1.3: Thick and thin filaments. shown are proteins called myosin (thick 
filament), actin, tropomyosin, troponin I, troponin C and troponin T, which are 
arranged to form a filamentous complex (thin filament). (Taken and edited from: 
Kamisago et al. 2000). 
 
Tropomyosin lies on either side of the actin, thus adding to the rigidity of the thin 
filaments and most importantly, it also influences the actin-myosin crossbridge 
formation by physically interdigitating between the actin-myosin cleft, therefore 
preventing Ca2+ binding (Katz et al. 1992; review by Walker and Spinale 1999). Also 
present in the thin filaments, is the troponin complex which is composed of three 
proteins i.e. troponin T, I and C, figure 1.3 (Davis et al. 2007). Troponin regulates the 
extent of crossbridge formation and contributes greatly to the structural integrity of 
the sarcomere (Lehman et al. 2009). Troponin T binds the troponin complex to the 
thin filament while phosphorylated troponin I weakens the affinity of Ca2+ for troponin 
C (Tikunova et al. 2002; Lehman et al. 2009). Binding of Ca2+ to troponin C results in 
conformational change of the complex with actin-myosin interaction that initiates 
crossbridge formation and power-stroke (Tikunova et al. 2002). 
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1.6 Myocardial energetics 
Energy metabolism is essential for normal contraction of the myocyte, as the heart 
uses between 3-5kg of ATP per day to keep pumping (Taegtmeyer 2002; Shah et al. 
2003; Doenst et al. 2008). At normal heart rates (~60 beats per minute) which take 
place when the body is at rest, a vast amount of energy is utilized by excitation-
contraction coupling (ECC) (Bers 2001; Maack and O‘Rourke 2007). It has been 
shown that the myosin ATPase, plasmalemmal Na+/K+-ATPase and sarcoplasmic 
reticulum Ca2+-ATPase are the main consumers of cellular energy in cardiomyocytes 
(Bers 2001; Doenst et al. 2008). In each normal heart beat ~2% of cellular ATP pool 
is consumed, while the whole ATP pool is turned over within couple of seconds 
during maximal workload (Harris and Das 1991; Mootha et al. 1997; Balaban 2002).  
 
It has been reported that the mitochondrion is the main site of energy production in 
cardiomyocytes (Balaban 2002; review by Maack and O‘Rourke 2007). Mitochondria 
are located in close vicinity to the main sites of energy consumption (myofilaments, 
SR and T-tubules) and occupy about one third (30%) of the cardiomyocyte space 
(figure 1.1) (Territo et al. 2001; Ormerod et al. 2008). The omnivorous cardiomyocyte 
can metabolise a wide variety of energy producing molecules such as lactate, ketone 
bodies and ethanol but under normal conditions the majority of ATP is supplied by 
fatty acids (60-90%) and glucose (10-40%) (Gertz et al. 1988; Young et al. 2002; 
review by Maack and O‘Rourke 2007). However, the heart normally responds to 
large variations in both substrate availability and energy demand, but has limited 
capacity for energy storage (Botker et al. 1994; Stanley et al. 2005). The β-oxidation 
(fatty acid metabolism to form acetyl-CoA) and glycolysis (glucose metabolism to 
form pyruvic acid) pathways are reciprocally controlled and overall ATP produced is 
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closely coupled to myofibrillar contraction (Stanley et al. 2005). Under normal 
physiological conditions, glucose is transformed to pyruvate, which then enters 
mitochondria and is further transformed by pyruvate dehydrogenase (PDH) to acetyl-
coenzyme A (acetyl-CoA) (Stanley et al. 2005). Fatty acids are converted to fatty 
acyl-CoA in the cytosol and transported into the mitochondria via the carnitine-
acyltranslocase (Grynberg and Demaison 1996). Mitochondrial acyl-CoA molecules 
are then broken down, resulting in the production of acetyl-CoA, reduced 
nicotinamide adenine dinucleotide (NADH) and reduced flavin adenine dinucleotide  
(FADH2) (Garland and Randle 1964; Goodwin et al. 1998b).  
 
Acetyl-CoA from both glycolysis and β-oxidation enters the tricarboxylic acid (TCA) 
cycle, leading to the formation of NADH and FADH2 (electron carriers) (Garland and 
Randle 1964; Taegtmeyer et al. 1980). Electrons from NADH and FADH2 flow 
through the electron transport chain to oxygen, during which energy is released and 
used to pump H+ ions across the inner mitochondrial membrane (Garland and 
Randle 1964; Taegtmeyer et al. 1980). The mitochondrial membrane contains 
various enzyme complexes that drive the synthesis of ATP from ADP and Pi (Stanley 
et al. 2005; review by Maack and O‘Rourke 2007). However, in pathological states 
such as diabetic cardiomyopathy, myocardial energy efficiency i.e. the ratio between 
cardiac work load and myocardial oxygen consumption is decreased, due to an 
increased reliance of the myocardium on fatty acid oxidation as an energy substrate 
(Boudina and Abel 2006). 
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1.7 Insulin signaling pathway 
Insulin, as mentioned above is a multifunctional peptide hormone that is composed 
of 51 amino acids with a molecular weight of about 5808 Da (Daltons) (Lomedico et 
al. 1979; Toriumi and Imai 2002). It is produced by pancreatic β-cells of the islets of 
Langerhans and its structure varies between animal species (Lomedico et al. 1979; 
Toriumi and Imai 2002). Insulin has a profound effect in metabolism by promoting the 
uptake of glucose, fatty acids and amino acids from the blood by the cells to be used 
or stored as glycogen, lipids and proteins (Lomedico et al. 1979; Cherrington 1999; 
Saltiel and Kahn 2001). When administered or endogenously released from the 
pancreas, insulin inhibits glucose production by hepatic cells and stimulates its utility 
by peripheral cells, therefore it is a primary regulator of glucose metabolism (review 
by Goalstone and Draznin 1997; Saltiel and Kahn 2001). 
 
Insulin also prohibits the use of fatty acids as energy source in the presence of 
excess plasma glucose by stimulating lipogenesis and diminishing lipolysis (review 
by Omerod et al. 2008). In addition, it is reported that insulin regulates gene 
transcription and increases amino acid transport into cells (Saltiel and Kahn 2001). 
Any disruption in the action of insulin such as in insulin resistance or deficiency, 
results in dysregulation of the above mentioned processes (Shulman et al. 1990; 
Cline 1994). There are several stimuli that may trigger the release of insulin by the 
pancreas, some of which are ingested proteins and glucose from digested food 
sources (Parker et al. 1983). 
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1.7.1 Glucose metabolism 
After a meal, blood glucose concentration increases drastically leading to the release 
of insulin from pancreatic β-cells (DeFronzo and Ferrannini 2001; De Myets and 
Whittaker 2002; Henriksen and Teachery 2007). Insulin binds onto its receptor 
located in the plasma membrane of the insulin sensitive cells (figure 1.4) (De Myets 
and Whittaker 2002; review by Frojdo et al. 2009). The insulin receptor is a 
glycosylated homodimer linked by disulfide bonds (Ring 2003; Hooper et al. 2007). It 
consist of two monomers each made up of an extracellular α-subunit and a β-subunit 
that spans the cell membrane (Sparrow et al. 1997; Hooper et al. 2007). The α-
subunits consist of insulin binding elements, while the β-subunit contains a protein-
tyrosine kinase domain in its intracellular portion and other domains involved in 
signal transduction pathways (Sparrow et al. 1997). Insulin binds to the α-subunits 
which induces a conformational change leading to autophosphorylation of tyrosine 
residues in the β-subunit (Van Obberghen et al 2001). 
 
Phosphotyrosine binding (PTB) domains, in proteins such as insulin receptor 
substrates (IRS) recognise these residues, bind to them and are activated (White 
2002). The activated IRS proteins then activate Src homology collagen (Shc) and 
adaptor protein with a pleckstrin homology (PH) and SRC homology-2 (SH2) domain 
(APS) (Alessi and Downes 1998; Hooper et al. 2007). These phosphorylated 
proteins stimulate downstream effector molecules, which then further activate 
different signaling pathways such as extracellular signal regulated kinase (ERK) 
pathway involved in growth (Van Obberghen et al. 2001). For metabolic effects of 
insulin the phoshatidylinositol 3-kinase (PI3K) is activated through IRS-1 (White 
2002; Gual et al 2005). IRS-1 is a tyrosine phosphorylated protein that belongs to the 
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IRS family of adaptor molecules, (section 1.7.2) (Kim et al. 1999; White 2002; 
Bouzakri et al. 2003). Activated PI3K enzyme phosphorylate inositol phospholipids in 
the plasma membrane, thus increasing the levels of phoshatidylinositol 3, 4, 5-
trisphosphate (PIP3) (Alessi and Downes 1998; review by Frojdo et al. 2009). This 
enables the recruitment and activation of serine/threonine kinase and 
phosphoinositide-dependent protein kinase (PDK1) which binds phospholipids 
through their PH domain (Van haesebroeck and Alessi 2000; Simpson et al. 2001; 
Beeson et al. 2003). PDK1 further phosphorylates and activates protein kinase C 
(PKC) and protein kinase B isoforms (PKB/Akt) (figure 1.4) (Van haesebroeck and 
Alessi 2000; Simpson et al. 2001). PKB/Akt will be discussed in section 1.7.3. PKC is 
involved in translocation of GLUT-4 (glucose transporter isoform), through 
phosphorylation of vesicle-associated membrane protein (VAMP)-2 protein located 
on GLUT-4 vesicles (Beeson et al. 2004). This results in GLUT-4 translocation to the 
plasma membrane, where GLUT-4 facilitates the import of glucose into the cell 
(Henriksen and Dokken 2006). Once inside the cell glucose is either used to produce 
energy or stored as glycogen for later usage (Henriksen and Dokken 2006). 
Glycogenesis is triggered by the rate limiting enzyme glycogen synthase and 
deactivated by glycogen synthase kinase-3 (GSK-3) through phosphorylation of 
glycogen synthase, therefore inhibiting it (figure 1.4) (Brady et al. 1998; Henriksen 
and Dokken 2006). 
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Figure 1.4: Insulin signaling pathway. Insulin initiates a signaling cascade that 
results in PKB/Akt-induced phosphorylation and inactivation of GSK-3β leading to 
the regulation of glycogen metabolism and protein synthesis (Grimes et al. 2001, 
Patel et al. 2004). IRS, insulin receptor substrate; PI3K, phosphatidylinositol 3 
kinase; PIP2, phosphatidylinositol-4,5-bisphosphate; PIP3, phosphatidylinositol-
3,4,5-trisphosphate; PDK1, phosphoinositide-dependent kinase-1; PKB/Akt , protein 
kinase B; GSK-3, glycogen synthase kinase-3; SERCA-2, 
Sarcoplasmic/endoplasmic reticulum Calcium (Ca2+) ATPase; PLM, phospholamban; 
eIF2B, eukaryotic initiation factor-2 beta. (Taken and edited from: Patel et al. 2004). 
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1.7.2 Insulin receptor substrate (IRS) proteins 
Insulin receptor substrates are tyrosine kinase proteins that mediate a variety of 
signaling pathways and their activities are induced by insulin, insulin like growth 
factors and cytokines (Kim et al. 1999; Kabuta et al. 2008). There are four members 
of IRS family namely IRS-1, IRS-2, IRS-3 and IRS-4 which range in order of their 
discovery (Kim et al. 1999; Vollenweider et al. 2002; Bouzarki et al. 2003). These 
proteins are best distinguished as docking or adaptor proteins for they couple the 
receptor to proteins containing a SH2 domain (Myers et al. 1995). First evidence for 
these substrate specific proteins came from studies done by White et al 1985, and 
IRS-1 was the first to be purified (Rothenberg et al. 1991; Myers et al. 1994; Waters 
et al. 1996). The open reading frame of the cDNA of IRS-1 protein has a molecular 
weight of ~131 kDa, while on SDS-PAGE it migrates between 165-180 kDa due to its 
high serine phosphorylation state (White et al. 1985; Myers et al. 1994).  
 
It is reported that IRS-1 has about 50 potential serine/threonine phosphorylation sites 
and 21 putative tyrosine phosphorylation sites located in the carboxy (COOH) 
terminal domain and these serve as binding sites for various SH2 containing proteins 
such as the p85 regulatory subunit of PI3K (Myers et al. 1995; Whitehead et al. 
2000; Gual et al. 2005). All four IRS proteins have a conserved domain structure with 
PH and phosphotyrosine binding (PTB) domains in the amino (NH2) terminus, 
enabling them to couple with the insulin receptor (Whitehead et al. 2000). For the 
purpose of the study, we will concentrate more on IRS-1 and IRS-2. 
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1.7.2.1 Regulation and specificity of IRS-1/2 proteins 
As mentioned above, IRS-1 and IRS-2 function as a link for the insulin receptor to its 
downstream molecules, thereby inducing biological actions, figure 1.4 (Kerouz et al. 
1997; Patel et al. 2004; Sherpherd 2005). This link is achieved through a series of 
intermediate effectors that bind to the tyrosine-phosphorylated motifs in IRS proteins 
via SH2 domains (Kerouz et al. 1997; Saltiel and Pessin 2003; Sherpherd 2005). 
PI3K is one of the examples of an SH2 domain containing protein (Vollenweider et 
al. 2002; Bousakri 2003.). PI3K plays an important role in several biological 
processes including growth and metabolism (Kerouz et al. 1997; Kim et al 1999; 
Bouzakri et al. 2003.). In metabolism, PI3K is involved in glucose transport, glycogen 
synthesis and inhibition of the key enzymes of gluconeogenesis (Cheatham and 
Kahn 1995; Sherpherd 2005). It has been shown that PI3K consists of a regulatory 
p85 subunit to which IRS-1 and IRS-2 bind via SH2 domains, and a 110 kDa 
catalytic subunit which phosphorylates phosphoinositidyl (PI) protein, and its 4‘ and 
4‘, 5‘ phosphorylated derivatives in the D-3 position of the inositol ring (Endemann et 
al 1990; Kerouz et al. 1997). In addition, it has been reported that IRS-1 is directly 
regulated by the insulin receptor (IR) which is stimulated by insulin (Cheatham and 
Kahn 1995; Vollenweider et al. 2002; White 2002). However, it has also been 
reported that IRS-1 is inhibited by GSK-3 through serine phosphorylation thus 
regulating it (Eldar-Finkelman and Krebs 1997). 
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1.7.2.2 Role of IRS-1/2 proteins in metabolism 
Evidence show that IRS-1 and IRS-2 play a direct role in insulin signaling especially 
in its metabolic actions but the exact role of IRS-3 and IRS-4 is poorly understood 
(Whitehead et al. 2000). However it is reported that IRS-3 and 4 overexpression in 
adipocytes may stimulate some of the activities of insulin (Whitehead et al. 2000). As 
mentioned previously, IRS-1 and IRS-2 are responsible for transmitting insulin 
signals from the insulin receptor to downstream intracellular effectors in the presence 
of glucose to maintain its homeostasis, figure 1.4 (Nandi et al. 2004; Thirone et al. 
2006).  
 
1.7.3 Protein kinase B/Akt (PKB/Akt) 
Protein kinase B also known as Akt is a serine/threonine protein kinase with a 
molecular weight of 57 kDa (Hajduch et al. 2001). It was discovered more than 10 
years ago and since then it has emerged as a critical signaling node in all eukaryotic 
cells and has been considered as the most important and versatile protein kinase in 
human physiology and diseases (Manning and Cantley 2007). PKB/Akt was so 
named because of its high homology with protein kinase A and C (PKA and PKC) 
(Hajduch et al. 2001). PKB/Akt was also called Akt due to the product of murine 
oncogene, v-Akt (Akt8 retrovirus) which turned out to be its cellular homologue (c-
Akt) (Coffer et al. 1998; Hanada et al. 2004).  
 
There are three PKB/Akt isoforms i.e. PKB/Akt1, PKB/Akt2 and PKB/Akt3 (α, β and 
) present in higher eukaryotes and each posess an amino terminal PH domain, a 
kinase domain and a carboxy terminal regulatory domain (Coffer et al. 1998; 
Hajduch et al. 2001). It is reported that α and β isoforms are ubiquitously expressed, 
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while the -isoform is relatively highly expressed in brain and testis only (Hanada et 
al. 2004).  
 
1.7.3.1 Regulation and specificity of PKB/Akt  
PKB/Akt is actively stimulated in response to insulin and growth factors through PI3K 
in a two step process, figure 1.4 (Hajduch et al. 2001). As shown in figure 1.4, the 
first step involves the stimulation of IRS proteins by insulin, which then activate PI3K 
resulting in the production of phosphoinositides PIP2 and PIP3 that are known to bind 
to the PH domain of PKB/Akt, therefore altering its conformation, leading to its 
phosphorylation and activation (Andjelkovic et al. 1997; Hajduch et al. 2001). 
PKB/Akt phosphorylation takes place at Threonine 308 (Thr308) of the kinase 
domain and Serine 473 (Ser473) of the C-terminal domain (Coffer et al. 1998; 
Vanhaesebroeck and Alessi 2000; Dong and Liu 2005). It is reported that PDK1 is 
responsible for the phosphorylation of PKB/Akt at Thr308 and PDK2 at Ser473 
(Alessi et al. 1997; Stokoe et al. 1997).  
 
Little is known about the mechanism in which PKB/Akt is inactivated, but it is stated 
that tumor suppressor PTEN (phosphatase and tensin homolog) acts as a 
phosphatase to dephosphorylate PIP3 back to PIP2, while PHLPP (PH domain and 
Leucine rich repeat Protein Phosphatases) directly dephosphorylate PKB/Akt 
isoforms (Stokoe et al. 1997; Lawrence and Roach 1997; Patel et al. 2004). This 
results in delocalization of PKB/Akt from the plasma membrane back to the cytosol 
decreasing the rate of its activation (Bayascas and Alessi 2005). It is also stated that 
PKB/Akt is the effector of PI3K signaling pathways in all cells including B cells where 
stimulated B cell receptor (BCR) can phosphorylate both PI3K and PKB/Akt (Ma et 
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al. 2008). All PKB/Akt isoforms are members of the AGC kinase family as they 
contain extensive homology to protein kinases A, G, and C (Manning and Cantley 
2007).  
 
1.7.3.2 Role of PKB/Akt in cells 
PKB/Akt-α is predominantly expressed in skeletal muscle, while PKB/Akt-β is the 
predominant isoform in adipocytes, but PKB/Akt- is active neither in skeletal 
muscles nor adipocytes (Hajduch et al. 2001). PKB/Akt is well established as the 
effector of PI3K signaling pathway in all cells (Fruman and Cantley 2002). As 
mentioned above, PKB/Akt is activated via PIP3, (figure 1.4) and when activated, it 
phosphorylates and controls the activities of several proteins involved in regulating 
cellular functions i.e. metabolism, growth, proliferation and cell survival (Yang et al. 
2004; Bayascas and Alessi 2005). 
 
In cell survival, PKB/Akt phosphorylate the BH3 domain-containing BAD protein 
which is a pro-apoptotic protein of Bcl-2 family (Clarke et al. 1994; review by Hajduch 
et al. 2001). BAD phosphorylation leads to its dissociation from Bcl-2/Bcl-X complex 
thus losing its pro-apoptotic effect (Wang et al. 1999; Cheatham et al. 1994; Faissner 
et al. 2006). PKB/Akt also regulates IkB kinase (IKK) and indirectly activates NF-kB 
resulting in pro-survival gene transcription (Cheatham et al. 1994; Faissner et al. 
2006). In glucose metabolism PKB/Akt is involved in translocation of glucose 
transporters (mainly GLUT 4) to the plasma membrane, thereby promoting glucose 
intake by the cells (Clarke et al. 1994; Wang et al. 1999; Hajduch et al. 2001). Once 
plasma glucose is available in excess, PKB/Akt phosphorylates GSK-3 which 
normally phosphorylates and inhibits the glycogen synthase, a rate limiting enzyme 
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of glycogenesis (Figure 1.4) (Lawrence and Roach 1997). Inhibition of GSK-3 by 
PKB/Akt favors glycogen synthesis and storage in muscles, liver and adipose tissues 
(Lawrence and Roach 1997; Hajduch et al. 2001). 
 
1.7.4 Glycogen Synthase Kinase-3 (GSK-3) 
The GSK-3 is a serine/threonine protein kinase that was discovered in the early 
1980s as an enzyme involved in regulation of glucose metabolism (Park et al. 2003). 
Its involvement in glucose metabolism increased researcher‘s interest and since 
then, it has been extensively researched especially in the context of metabolic 
actions of insulin (Woodgett, 2001; review by Huisamen and Lochner 2010). Studies 
have shown that GSK-3 phosphorylates and inhibits glycogen synthase and insulin 
receptor substrate-1 (IRS-1) activity thereby impairing insulin signaling (Eldar-
Finkelman et al. 1996).  
 
It has been discovered that GSK-3 is not only involved in glucose metabolism, but is 
a multifunctional protein kinase that performs a role in several signaling pathways 
such as in the regulation of cell fate, including Wnt (wingless) and Hedgehog signal 
transduction, protein synthesis, mitosis and apoptosis (review by Forde and Dale 
2007). GSK-3 has been implicated, when dysregulated, in the development of 
human diseases such as diabetes, Alzheimer‘s disease, bipolar disorder and cancer 
(review by Doble and Woodgett 2003). GSK-3 was originally identified in mammals, 
but other homologues have been discovered in all eukaryotes (Rylatt et al. 1980). All 
GSK-3 homologues share a significant degree of sequence homology ranging from 
species as distant as humans and drosophila that share over 80% similarity within 
the kinase domains (review by Ali et al. 2001).  
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1.7.4.1 GSK-3 isoforms 
In humans, two GSK-3 isoforms have been identified, GSK-3α with a molecular 
weight of ~51 kDa and GSK-3β with a molecular weight of ~47 kDa (figure 1.5) 
(Woodgett 1990; Ciaraldi et al 2007). These isoforms are encoded by two distinct 
genes located on chromosomes 19q13.1-2 and 3q13.3-q21. As a result they exhibit 
a high degree of sequence similarity in their catalytic domains (Ciaraldi et al 2007; 
Markou et al. 2008). Exact cytological locations of these isoforms have been 
identified using chromosomal mapping, i.e. GSK-3α is located at 19q13.2 and GSK-
3β maps to 3q13.3 (Shaw et al. 1998; review by Ali et al. 2001). They exhibit about 
98% homology in their kinase domains, but they share only about 36% identity in the 
last 76 C-terminal amino-acid residues (figure 1.5) (Woodgett 1990). 
 
 
Figure 1.5: Schematic representations of GSK-3α and GSK-3β isoforms. Blue arrow-
heads indicate sites of serine and tyrosine phosphorylation. A glycine-rich N terminal 
domain of GSK-3α and a conserved kinase domain from both GSK-3α/β are 
highlighted (Taken from: Doble and Woodgett 2003) 
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Although these isoforms are structurally similar, their expression patterns, substrate 
preferences and cellular functions are not identical (Woodgett 2001; review by Doble 
and Woodgett 2003). Hoeflich et al. 2000 reported that mice embryos carrying 
homozygous deletions of exon 2 of the GSK-3β isoform suffer from a massive liver 
degeneration caused by extensive hepatocyte apoptosis, leading to death at around 
embryonic day 16. GSK-3α isoform was unable to take over the function of GSK-3β 
in these GSK-3β null mice, indicating that the degenerative liver phenotype develops 
specifically from the loss of GSK-3β isoform (review by Doble and Woodgett 2003).  
 
1.7.4.2 Regulation and specificity of glycogen synthase kinase-3 (GSK-3) 
1.7.4.2.1 Regulation of GSK-3 protein 
GSK-3 is, unlike most other protein kinases, active in the resting state and 
deactivated when cells are stimulated (Woodgett 1994; Hirotani et al 2007). The 
most well defined mechanism of GSK-3 regulation is the phosphorylation of Serine 9 
(Ser9) in GSK-3β and Ser21 in the GSK-3α isoform (Markou et al. 2008; Miron 
2008). This is accomplished by hormones such as insulin, endothelial growth factor 
and platelet growth factor (Ciaraldi et al. 2007). In cells, insulin stimulates glycogen 
synthesis both by inhibiting GSK-3 and dephosphorylation of glycogen synthase (Ali 
et al. 2001). PKB/Akt (PI3K pathway), some isoforms of protein kinase C (PKC), 
PKA, p90RSK and p70S6 kinase may all be responsible for phosphorylation of GSK-3 
on serine residues located at the N-terminus, thus inactivating it (Murphy and 
Steenbergen 2005). GSK-3 is also inhibited by cardiac hypertrophic stimuli, including 
endothelin-1, Fas, and pressure overload, possibly through the PI3K-PKB/Akt 
pathway (Haq et al. 2000; Badorff et al. 2002). 
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It has been demonstrated that a phosphor-peptide based on the N-terminus of GSK-
3β acts as a competitive inhibitor of the primed GSK-3 substrates (Dajani et al. 
2001). These findings led to the suggestion that the phosphorylated N-terminus of 
GSK-3 protein auto-inhibits its activity by looping back into its active site (review by 
Forde and Dale 2007). Phosphorylated N-terminus also serve as a pseudo-substrate 
that binds to the positively charged pocket, consisting of Arg96, Arg180, and Lys205, 
therefore competing with primed substrates for binding to the catalytic groove (Miron 
2008). In contrast to inactivation via serine phosphorylation, GSK-3 can also be 
phosphorylated on tyrosine residues resulting in its activation, i.e. tyr-279 of GSK-3α 
and tyr-216 of the GSK-3β isoform (Murphy and Steenbergen 2005). This means 
GSK-3 tyrosine phosphorylation results in facilitative autophosphorylation while 
serine phosphorylation is regulatory (Markou et al. 2008). The kinase responsible for 
tyrosine phosphorylation of GSK-3 protein is poorly understood but it has been 
reported that calcium sensitive protein-tyrosine kinase-2 might be responsible 
(Hartigan and Johnson 1999).  
 
GSK-3 activity can also be regulated by protein interactions, e.g. it is usually 
complexed with β-catenin, axin and adenomatous polyposis coli (APC) proteins 
(Murphy and Steenbergen 2005). Disruption of such a complex by displacement of 
axin by other proteins such as dishevelled and frequently rearranged during 
advanced T cell lymphomas (FRAT), a.k.a. GSK-3 binding protein, blocks GSK-3β 
association with β-catenin, resulting in reduction of β-catenin phosphorylation (Hinoi 
et al. 2000). Other mechanisms resulting in GSK-3 regulation besides 
phosphorylation have been employed, one of which is the control of subcellular 
localization (Miron 2008). That is, specific substrate phosphorylation may be 
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regulated by targeting GSK-3β to a specific location or binding partner (Murphy and 
Steenbergen 2005). GSK-3β can be targeted by different stimuli to the nucleus or 
mitochondria where it acts on a subset of cellular substrates (Juhaszova et al. 2004). 
For example, during the G1 phase of the cell cycle, GSK-3β is predominantly 
cytoplasmic, but during the S phase, a significant fraction enters the nucleus 
promoting its ability to phosphorylate cyclin D1 in the nucleus (Diehl et al. 1998; 
Miron 2008). 
 
In cardiomyocytes, GSK-3β has been shown to be present in both nucleus and 
cytosol under normal, unstimulated conditions (Murphy and Steenbergen 2005). It 
has been reported that nuclear localisation of GSK-3β is enhanced by endothelin 
(Morisco et al. 2001). Upstream kinases such as PKB/Akt can also be targeted to 
GSK-3 in specific locations (Morisco et al. 2001). However, the export of GSK-3β 
from the nucleus is achieved by addition of isoprenaline (Morisco et al. 2001). In 
addition to that, GSK binding protein (FRAT) has also been shown to enhance 
nuclear export of GSK-3β (Franca-koh et al. 2002).  
 
1.7.4.2.2 Specificity of GSK-3 protein 
When activated, GSK-3 preferentially targets the proteins that are pre-
phosphorylated at a priming residue located four residues C- terminal to the GSK-3 
phosphorylation site (Eldar-Finkelman 2002; Patel et al. 2004). It has been reported 
that priming phosphorylation of most of GSK-3 substrates enhances the efficiency of 
their phosphorylation and provide a means for GSK-3 to integrate multiple signaling 
pathways (Patel et al. 2004; Murphy and Steenbergen 2005). 
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GSK-3 is considered as a selective serine/threonine kinase that recognizes and 
phosphorylates the consensus sequence T/SXXXT/S(P) or S1xxxS2(p) where ‗X‘ is 
any amino acid and ‗(P)‘ is the phosphorylatable residue in certain proteins (Fiol et al 
1990; Patel et al. 2004). The S2(p) represents the priming site. However, certain 
substrates such as c-Jun, c-Myc and c-Myb do not follow the S1xxxS2(p) motif and 
do not require pre-phosphorylation (Plyte et al. 1992). Whether the substrate is pre-
phosphorylated or not, its phosphorylation by GSK-3 attenuates its function (Eldar-
Finkelman 2002). 
 
1.7.4.3 Targets of GSK-3 
GSK-3 does not only target glycogen synthase but there are a number of other 
substrates identified, including translation initiation factor eIF2B(epsilon), PKA, 
phosphatase subunit RGI and ATP-citrate lyase (Woodgett et al. 1993). In addition, 
GSK-3 also phosphorylates several transcription factors which include CREB, c-Jun, 
c-Myc, c-Myb as well as heat shock transcription factor HSF-1 (Xavier et al. 2000; Ali 
et al 2001). Some of the targets of GSK-3 are brain associated proteins such as 
amyloid precursor protein, Tau and neurofilament proteins (Plyte et al. 1992). It is 
reported that phosphorylated Tau has a lower affinity for microtubules and when 
hyper-phosphorylated it seems to promote association into paired helical filaments 
which is a pathological feature of Alzheimer‘s disease (Spittaels et al. 2000). In 
addition GSK-3 is also known to phosphorylate IRS-1 thus inhibiting insulin signaling 
(Eldar-Finkelman and Krebs 1997). Furthermore, GSK-3 substrate phosphorylation 
is generally inhibitory to its substrate, meaning that GSK-3 is a suppressor of these 
target proteins (Miron 2008). 
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1.7.4.4 GSK-3 and myocardial contractility (Calcium homeostasis) 
It has been reported that GSK-3 protein plays an important role in the regulation of 
calcium homeostasis in the heart (Michael et al. 2004; Omar et al. 2010). In 
cardiomyocytes, calcium homeostasis is directly regulated by 
sarcoplasmic/endoplasmic reticulum Calcium (Ca2+) ATPase (SERCA)-2a, also 
known as calcium ATPase pump (section 1.7.5) (Takeda 2010). However, it has 
been reported that GSK-3 down regulates the expression of the SERCA-2a protein, 
by acting directly on its promoter to lower the mRNA levels (Michael et al 2004). The 
attenuation of SERCA-2a expression in the heart may lead to contractile 
abnormalities such as systolic and diastolic dysfunction (Dutta et al. 2002; Michael et 
al. 2004; Wold et al. 2005). GSK-3β is also known to play a role in the regulation of 
cardiac growth and hypertrophy (Haq et al. 2000; Bardorf et al 2002). Cardiac 
hypertrophy can be physiological or pathological (review by Huisamen and Lochner 
2010).  
 
The association between pathologic hypertrophy and activation of neuro-humoral 
pathways i.e. endothelin I, angiotensin II and catecholamines, that lead to the 
release of calcium from the sarcoplasmic reticulum (SR), has been reported 
(Blankesteijn et al. 2008; review by Huisamen and Lochner 2010). The calcium 
released from the SR will then eventually activate the calcium dependent 
phosphatase called calcineurin, which regulates alterations in gene expression 
associated with hypertrophy (Blankesteijn et al. 2008). Pathologic hypertrophy of the 
cardiomyocytes may result in heart failure, a leading cause of death in developed 
countries (Haq et al. 2000). By using adenovirus-mediated gene transfer of GSK-3β 
containing a ser-9 to alanine mutation, Haq and colleagues demonstrated that the 
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inactivation of GSK-3β protein is required in order for the cardiomyocyte to undergo 
hypertrophy. They suggested that GSK-3β regulates the hypertrophic response, by 
modulating the nuclear/cytoplasmic partitioning of a member of the nuclear factor of 
activated T cell family of transcription factors (Haq et al. 2000).  
 
1.7.4.5 GSK-3 in diabetes and insulin resistance 
Diabetes mellitus is the most common metabolic disorder, affecting about 150 million 
people worldwide and is expected to double within the next 20 years (Cohen and 
Goedert 2004). Type II diabetes develops when the insulin sensitive tissues are 
resistant to insulin, thus hindering glucose transport and metabolism (Meijer et al. 
2004). It has been reported that insulin decreases GSK-3 mediated inhibition of 
glycogen synthase, and thereby increases the activity of the latter (Meijer et al. 
2004). It has also been reported that GSK-3 is one of the factors associated with the 
reduction of insulin action in skeletal muscle, liver, and adipose tissues (Henriksen 
and Dokken 2006). Most studies reported that GSK-3 is upregulated in muscles of 
both obese rodents and obese, type II diabetic humans (review by Herinksen and 
Fokken 2006). In addition, it has been shown that in skeletal muscle of obese 
rodents and type II diabetic humans, activated GSK-3 impairs insulin signaling by 
serine phosphorylation of IRS-1, thereby negatively regulating glucose uptake 
(Eldar-Finkelman et al. 1997). 
 
The evidence from a variety of obese rodent models and type II diabetic humans 
supports a role for GSK-3 overactivity in the development of insulin resistance of 
glucose transport and glycogen synthesis (Embi et al. 1980; Henriksen and Dokken 
2006). In addition to insulin resistance, animal models overexpressing GSK-3 also 
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presented with attenuated SERCA-2a expression in the heart resulting in contractile 
abnormalities (Pearce et al. 2004; Michael et al. 2004). As mentioned earlier, GSK-3 
regulates through phosphorylation the activity of several metabolic enzymes 
including glycogen synthase (Embi et al. 1980). It has been reported that 
pharmacological GSK-3 inhibition potentiates insulin action in skeletal muscle of 
insulin resistant rats (Henriksen at al. 2003). 
 
1.7.4.6 GSK-3 Inhibition 
Diseases such as diabetes, Alzheimer‘s disease and some cardiovascular disorders, 
are associated with abnormalities in phosphorylation of proteins involved in 
regulation of signaling pathways (Noble et al. 2004; Martinez 2008). As a result, 
pharmaceutical companies are more interested in the development of 
pharmacological inhibitors of kinases and phosphatases (Martinez 2008). GSK-3 is 
one of the kinases that flared the interest to develop new generations of inhibitors 
with specific clinical implications (Martinez 2008). It has been reported that, in the 
heart, GSK-3 inhibition plays a crucial role in the protection against ischemic damage 
at the level of mitochondrial functioning as it keeps the mitochondrial permeability 
transition pore in a closed conformation (Juhaszova et al. 2004). The opening of this 
pore leads to cell death (Juhaszova et al. 2004).  
 
In addition, it has been shown that inhibition of GSK-3β by the PI3K/PKB/Akt 
pathway provides cardioprotection and it is an attractive target in ischemia-
reperfusion injury (reviewed by Kumar et al. 2007). Other studies using highly 
selective GSK-3 inhibitors indicated that the overactivation of GSK-3 protein in 
obesity is indeed associated with enhanced IRS-1 phosphorylation, and defective 
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IRS-1 dependent signaling which results in reduced glucose transporter (GLUT)-4 
translocation in skeletal muscle (Liberman and Eldar-Finkelman 2005; Henriksen et 
al. 2003).  
 
There are three distinct regions of GSK-3 that are targeted by inhibitors to suppress 
its activity i.e. Metal ion (Mg+2) binding site, substrate interaction domain and ATP 
binding pocket (Van Wauwe and Haefner 2003). However, most of the GSK-3 
inhibitors are known to compete with ATP to bind to its pocket (Patel et al. 2007). 
There are several types of GSK-3 inhibitors reported, ranging from hymenialdisine, 
paullones and indirubins, but they are also known to inhibit other protein kinases 
related to GSK-3 such as Cyclin-Dependant protein kinases (CDKs) resulting in side 
effects (Meijer et al. 2003; Leost et al. 2000).  
 
Lithium (Li+) was the first GSK-3 inhibitor to be discovered and since then it has been 
widely used as a pharmacological inhibitor (Klein and Melton 1996; Meijer et al. 
2004). Lithium was originally used as a mood stabilizer in the nineteenth century and 
was considered as an effective treatment for both acute and long-term phases of 
manic depression (Williams et al. 2004). Lithium chloride (LiCl) is the most 
commonly used GSK-3 inhibitor (Stambolic et al. 1996). It non-specifically inhibits 
both GSK-3α and GSK-3β isoforms in vitro and in vivo (Klein and Melton 1996). This 
is accomplished through competition for Mg2+ binding at a site distinct from the ATP 
binding pocket (Ryves et al. 2002). However, there are other specific, potent and 
selected cell permeable GSK-3 inhibitors, including SB-216763, SB-415286 and 
Chirone, CHIR118637 (CT20026) reported (Coghlan et al. 2000). The GSK-3 
inhibitors that act in the distal part of the insulin signaling pathway might represent a 
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promising opportunity to treat insulin resistance and type II diabetes (Van Wauwe 
and Haefner 2003; Cohen and Goedert 2004). 
 
1.7.5 Sarcoplasmic/endoplasmic reticulum Calcium (Ca2+) ATPase (SERCA) 
SERCA is an intracellular membrane bound enzyme that belongs to the ―P‖ family of 
cation transport ATPases which include plasma Ca2+ ATPase (PMCA), Na+/K+ 
ATPase and H+/K+ ATPase (Sweadner and Donnet 2001; Inesi et al. 2005). P-type 
ATPases transfer the terminal phosphate of the ATP molecule to an aspartate 
residue in the catalytic domain, resulting in a reversible conformational change that 
helps the movement of ions across the biological membranes (Periasamy and 
Kalyanasundaram 2007). SERCA transports calcium (Ca2+) ions from the cytoplasm 
into the sarcoplasmic reticulum (SR), against its concentration gradient through the 
use of free energy of ATP and it is therefore considered as a pump (Inesi et al. 
2005). That is, two calcium ions are transported per ATP hydrolysis (Periasamy and 
Kalyanasundaram 2007).  
 
SERCA pump is a single polypeptide of about 110 kDa, localized in both 
endoplasmic reticulum (ER) and sarcoplasmic reticulum (SR) (Periasamy and 
Kalyanasundaram 2007). Large domains in the cytoplasm contain both a 
phosphorylation site (Asp351) and a nucleotide binding site, while residues in four 
(M4, M5, M6 and M8) of the 10 trans-membrane helices form a Ca2+ translocating 
pocket (MacLennan et al 1997). It has been identified in both prokaryotes and 
eukaryotes and is also known to be present in all living organisms, from yeast and 
plants to the mammalian system (Periasamy and Kalyanasundaram 2007). 
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1.7.5.1 SERCA pump isoforms 
There are three distinct genes encoding SERCA-1, 2 and 3 that are known to 
produce more than 10 isoforms in vertebrates (Periasamy and Kalyanasundaram 
2007). SERCA-1 is mainly expressed in fast-twitch skeletal muscle and is 
alternatively spliced to encode SERCA-1a (994 amino acids, adult) and SERCA-1b 
(1011 aa, fetal) (Brandl et al. 1987). SERCA-2 encodes three isoforms i.e. SERCA-
2a, b and c. SERCA-2a consist of about 997 amino acid residues and is 
predominantly expressed in cardiac and slow twitch skeletal muscle (MacLennan et 
al. 1985). SERCA-2b, which is about 1042 amino acid sequence long, is expressed 
in all tissues at low levels including muscle and nonmuscle cells (Dode et al. 2002). 
Recently discovered SERCA-2c is 999 amino acids long and has been reported in 
cardiac muscle (Dally et al. 2006).  
 
SERCA-3 isoforms are expressed in several nonmuscle tissues and appear to be a 
minor form in muscles (Wuytack et al. 1994). However, SERCA-3 is known to 
encode for 6 isoforms (3a-3f) in humans ranging between 999-1052 amino acids in 
length at the mRNA level and are expressed in multiple tissues and cell types (Bobe 
et al. 2005). At protein level, only SERCA-3a,b,c isoforms are evidenced and are 
known to be expressed at high levels in the hematopoietic cell lineages, platelets, 
epithelial cells, fibroblasts and endothelial cells (Anger et al. 1993). For the purpose 
of the study we will focus more on SERCA-2a isoform which is critical for cardiac 
functioning. 
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1.7.5.2 Role of SERCA-2a in cardiac muscle contraction and relaxation 
As mentioned previously, SERCA-2 gene encodes three different protein isoforms, 
however in the current study we will focus on SERCA-2a which is muscle specific 
and a ubiquitously expressed SERCA-2b isoform (Periasamy and Kalyanasundaram 
2007). These two isoforms differ at the C-terminal domain, where the last four amino 
acids of the expressed SERCA-2a are replaced by an extended tail of 49 amino 
acids in SERCA-2b isoform (Periasamy and Kalyanasundaram 2007). Precise 
control of cytosolic and SR Ca2+ concentration is important in maintaining both 
systolic and diastolic functions (Michael et al. 2004; Fang 2003; Cosson and 
Kevorkian 2003). In addition, a derangement in Ca2+ homeostasis is a primary cause 
of myocardial contractile abnormalities in heart failure (Dutta 2002; Wold et al. 2005; 
Shattock 2009). SR is an intracellular membranous network found in all muscle cells, 
which plays a major role in the contraction-relaxation cycling of the myocardium by 
regulating its intracellular Ca2+ concentrations (Lytton et al. 1992).  
 
Intracellular calcium is stored and released from the SR and it serve as a critical 
determinant of myocardial contractility (Gyorke and Carnes 2008). The total SR Ca2+ 
content in the mammalian cardiomyocyte has been estimated to be in the range of 
50-150 µmol/l in the cytosol (or 1.4-3 mmol/l of SR volume), considering that SR 
comprises 3.5% of the cell volume (Bers 2002a). As mentioned previously, 
sequestration of Ca2+ by the calcium pump (SERCA-2a) of the SR membranes 
accounts for the major portion of Ca2+ removed from the cytosol during myocardial 
relaxation (Negretti et al. 1993). Therefore SERCA-2a plays a pivotal role in the 
regulation of cardiac functioning i.e. it is a principal means by which cytoplasmic 
calcium is lowered during relaxation and it is also a principal determinant of the Ca2+ 
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concentration in the sarcoplasmic reticulum, which in turn, determines contractility 
due to its influence on the magnitude of Ca2+ release (Asahi et al. 2003). Therefore, 
factors that affect/regulate SR calcium pump (SERCA-2a) activity are expected to 
have a marked effect on the mechanical properties of the heart (Takeda 2010).  
 
1.7.5.2.1 Myocardial contraction 
Myocardial contraction and relaxation involves the movement of calcium ions into 
and out of the cytoplasm of each myocyte (Woodcock and Matkovich 2005; Peskoff 
and Langer 1998). Thus, intracellular calcium handling is the central co-ordinator of 
cardiac contraction and relaxation (Berridge 2003). Traditionally, myocardial 
contraction begins with excitation-contraction coupling, a process involving electrical 
excitation of the myocytes leading to contraction of the heart (Bers 2002b). During 
the cardiac action potential (AP) (section 1.5.1.2), voltage-gated Na+-channels are 
activated, and the inward Na+-current (INa) induces a rapid depolarization of the cell 
membrane (Maack and O‘Rourke 2007). This results in opening of the voltage-
dependent L-type Ca+ channels (Ica,L) and Ca
+ enters the cell (Asahi et al 2003; 
Maack and O‘Rourke 2007).  
 
Ca+ influx triggers the opening of the ryanodine receptors (RyR2 subtype), which 
release even greater amounts of Ca2+ from the SR, a process called Ca2+ induced 
Ca2+ release (CICR) (Fabiato 1985; Bers 2001). The dydic or junctional cleft, a gap 
or space of typically ~10 nm found between the SR and the cell membrane is then 
flooded by the Ca2+ released from RyRs and which then cover a volume with a 
radius of about 200 nm (Peskoff and Langer 1998). This high junctional [Ca2+] rapidly 
decays by diffusion into the submembrane space, then further into the bulk cytosol 
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(Weber et al. 2002). Increased cytosolic Ca2+ binds to troponin C in the myofilaments 
and induces conformational changes, which subsequently allow the globular myosin 
head to interact with actin-binding site of the thin filaments resulting in contraction of 
the left and right ventricle (Schmidt et al. 2002). This leads to the ejection of blood 
through the aortic and pulmonary valves of the heart respectively, and initiating 
systole (Maack and O‘Rourke 2007). 
 
1.7.5.2.2 Myocardial relaxation 
Myocardial relaxation is achieved by diffusion of Ca2+ from the myofilaments back to 
the cytosol (Michael et al. 2004). The main mechanism of removing cytosolic Ca2+ 
(back to the SR) involves the SR Ca2+-ATPase (SERCA-2a), sarcolemmal Na+/ Ca2+-
exchanger (NCX) and the plasmalemmal Ca2+-ATPase (PMCA) (Bers et al. 2002a). 
Ca2+ is predominantly re-sequestered into the SR lumen by SERCA-2a and the 
remaining amount is extruded from the cell by NCX and PMCA (Schmidt et al. 2002). 
SERCA-2a plays an important role in mammalian cardiac muscle relaxation by 
acting as a regulator of calcium homeostasis (Periasamy and Huke 2001). As 
mentioned above, SERCA-2a transports calcium (Ca2+) ions from the cytoplasm into 
the sarcoplasmic reticulum (SR), against its concentration gradient through the use 
of free energy of ATP (Inesi et al. 2005).  
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1.7.5.3 Regulation of SERCA-2a 
SERCA-2a activity is regulated by phospholamban (PLM) (figure 1.4) and its 
homologue protein, sarcolipin (SLN), through direct protein-protein interactions 
(Asahi et al. 2002). PLM inhibits SERCA-2a by lowering its affinity for Ca2+ (Asahi et 
al. 2002). SERCA-2a-PLM interaction is regulated by Ca2+ concentration i.e. 
elevation in Ca2+ concentration leads to the dissociation of the SERCA-2a-PLM 
complex while lower concentrations of Ca2+ results in SERCA-2a-PLM complex 
formation (James at al. 1989). Toyofuku et al. 1994, suggested that there are three 
sites of interaction between SERCA-2a and PLM. The first is a cytoplasmic 
interaction site that is formed by charged and hydrophobic amino acids in the IA 
domain of PLM and by amino acids Lys-Asp-Asp-Lys-Pro-Val402 in SERCA-2a 
(Toyofuku et al. 1994). The second is also a cytoplasmic interaction site formed by 
the PLM domain IB and the transmembrane domain M4 of SERCA-2a (Toyofuku et 
al 1994; Kimura et al. 1998). The third interaction site is between PLM domain II and 
SERCA-2a transmembrane helix M6 (Asahi et al. 1999).  
 
It has been reported that a decrease in Ca2+ uptake is a central feature of heart 
failure in humans and animals (Sordahl et al. 1973; Whitmer et al. 1988). In addition, 
it has been shown that, a relative increase in PLM to SERCA-2a ratio is an important 
determinant of SR dysfunction in heart failure (Meyer et al. 1995; Hasenfuss 1998). 
Sarcolipin (SLN) is a 31 amino acid SR membrane protein that interacts with and 
inhibits SERCA-2a by lowering its Ca2+ affinity and Vmax (Asahi et al. 2003). SLN is 
predominantly expressed in fast-twitch skeletal muscle in human and is less 
expressed in cardiac and slow-twitch skeletal muscle (Odermatt et al. 1997). 
However, SLN is more expressed in rat cardiomyocytes than in human cardiac 
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muscle (Gayan-Ramirez et al. 2000). In addition to lowering the Ca2+ affinity and 
reducing the Vmax of SERCA-2a, SLN also enhances the inhibitory effects of PLM on 
SERCA-2a in vitro (Asahi et al. 2002; Asahi et al. 2003). This is because of its ability 
to bind directly to PLM and prevent PLM from polymerization, resulting in an 
increase in the active form of PLM (monomer) (Asahi et al 2003). However, it has 
been reported that PLM has a stronger affinity for the SERCA-2a binding site than 
SLN, but SLN may have additional interactions with the SERCA-2a-PLM complex 
(Asahi et al. 2003; Vittorini et al. 2007). In general, SLN can regulate SERCA-2a by 
inhibiting it through direct interaction with SERCA-2a or by stabilizing the SERCA-2a-
PLM complex (Asahi et al 2003; Vittorini et al. 2007). 
 
1.7.6 Phospholamban (PLM) 
Phospholamban is a 52 amino acid integral membrane protein that regulates 
SERCA-2a in cardiac and skeletal muscle cells (Rodriguez and Kranias 2005). In 
vitro studies have shown that phospholamban structure appears as a pentamer, that 
is composed of 6000 Da subunits and it is located in the SR of cardiac, slow twitch 
skeletal and smooth muscles (Schmidt et al. 2002). It has been suggested that 
although PLM mainly exists as a homopentamer, its functionally active form is a 
monomer and the pentamer probably act as a reservoir (Zvaritch et al. 2000). There 
are currently no isoforms of phospholamban known and therefore it is considered as 
a single copy gene (Simmerman and Jones 1998). The structure of PLM is 
organized into two main domains (i.e. Domain I and II). Domain I (amino acids 
residues 1-30) is hydrophilic and it constitutes the cytoplasmic sector and it can be 
subdivided further into two motifs i.e. domain Ia (residues 1-20) which has been 
reported to form an α helical structure and domain Ib (residues 21-30) which usually 
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exists as a random coil (MacLennan et al. 1998; Simmerman and Jones 1998). 
Domain II (amino acids 31-52) consists of a hydrophobic membrane spanning part of 
the protein and it has also been proposed to have an α-helical structure which 
stabilizes the phospholamban pentamer (Kadambi and Kranias 1997; Simmerman 
and Jones 1998). 
 
1.7.6.1 Role and regulation of PLM  
PLM in its unphosphorylated state, is known to inhibit SERCA-2a activity, however, 
when phosphorylated it dissociate from SERCA-2a (Luo et al. 1998; Minamisawa et 
al. 1999). It has been reported that, under normal physiological conditions, PLM 
phosphorylation on its serine residue is the main predominant event that leads to 
increased rates of Ca2+ uptake into the SR and accelerated relaxation (Tada et al. 
1982; Luo et al. 1998). In addition, it has recently been shown that PLM forms an 
integral part of the Na+/K+ pump complex and provides the link between kinase 
activation and modulation of pumps (Silverman et al. 2005). This binding of PLM to 
the Na+/K+ pump begins with β-adrenergic receptor stimulation in the intact heart 
which is chronotropic, inotropic and lusitropic (Shattock 2009). Inotropic and 
lusitropic effects are primarily due to the activation of the cAMP-dependent kinase 
(PKA) which takes place after the elevation of the second messenger cAMP 
(Shattock 2009). 
 
In vitro studies, using purified cardiac SR membranes, have shown that PLM can be 
phosphorylated by PKA at serine-16, Ca2+/ calmodulin-dependent protein kinase at 
Threonine-17 and PKC at Serine-10, thus inhibiting it (Simmerman et al. 1986; 
Silverman et al. 2005; Shattock 2009). PKA activation has four main consequences 
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i.e. 1) an increase in L-type Ca2+ current, 2) an increase in recycling of Ca2+ back 
into the SR which follows PLM phosphorylation, 3) an increased rate of Ca2+ 
dissociation from the myofilaments following phosphorylation of troponin I, and 4) an 
increase in intracellular Na+ which is due to increased heart rate and changes in the 
control of intracellular Ca2+ via Na+/Ca2+ exchanger (Shattock 2009). PLM plays an 
essential role in the protection of the heart from Na+ and Ca2+ overload during β-
receptor stimulation (Shattock 2009). In addition, studies have shown that an 
increase in heart rate in the absence of β-adrenergic stimulation can lead to 
phospholamban (PLM) phosphorylation at Threonine-17 (Thr-17) through a process 
that involves the generation of nitric oxide (NO) from nNOS (Zhao et al. 2004; Sears 
et al. 2004). 
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1.8 Motivation, aims and objectives of this study 
1.8.1 Motivation 
To understand the causes and aetiology of the development of the cardiovascular 
pathology (cardiomyopathy) in obesity, in the current study we have focused on the 
insulin signaling pathway. Previous studies conducted in our laboratory, 
demonstrated this pathway to be insensitive to insulin stimulation in hearts from a 
model of diet induced obese (DIO) rats (du Toit et al. 2008). One of the abnormalities 
observed in this pathway, is an inability of insulin to stimulate PKB/Akt, which is 
known to mediate the metabolic effects of insulin such as glycogen synthesis and 
glucose uptake (unpublished results). The cardiomyocytes from these diabetic hearts 
also present with an inability to take up glucose on insulin stimulation (Patel et al. 
2004). As mentioned previously, prior to the activation by insulin, PKB/Akt directly 
regulates the activity of GSK-3 (Lawrence and Roach 1997). 
 
It has also been reported that GSK-3 protein is upregulated in muscles of both obese 
rodents and type II diabetic humans (review by Henriksen and Dokken 2006). This 
has been associated with decreased whole body insulin sensitivity and attenuated 
expression of the SERCA-2a protein in cardiomyocytes (Michael et al. 2004). 
However, in the context of protection via pre-conditioning, most studies focused 
more on GSK-3β than the GSK-3α isoform. As it is well known that the activity of 
PKB/Akt protein is suppressed in the insulin resistant state (Vollenweider et al. 2002; 
Bouzakri et al. 2003), we postulate that GSK-3 expression and activity will be 
upregulated in the hearts from obese rodents and that this may lead to the 
development of cardiomyopathy. As far as we understand, this has not yet been 
investigated. 
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In addition, a new range of selective and more specific GSK-3 inhibitors is currently 
under development (review by Henriksen and Dokken 2006). But the cardiovascular 
effects or long-term treatment effects of these inhibitors in obesity and insulin 
resistance have not been investigated. However, it has been shown that a 20 day 
treatment period of obese mice resulted in improved whole body insulin sensitivity 
(Rao et al. 2007). In addition, it is known that the inhibition of myocardial GSK-3 
protein plays a role in the protection against ischemic damage at the level of 
mitochondrial functioning (Juhaszova et al. 2004). However, the expression, 
regulation or dysregulation and the intracellular compartmentalization of the GSK-3 
protein in the heart, in states of obesity and insulin resistance is currently unknown. 
We therefore propose to use a selective GSK-3 inhibitor to elucidate the role of the 
GSK-3 protein in the development of the diverse detrimental myocardial effects 
resulting from obesity and insulin resistance. 
 
1.8.2 Hypothesis 
We hypothesize that GSK-3 protein and its substrate proteins play a role in the 
development of cardiomyopathy associated with obesity and insulin resistance. In 
addition, we also hypothesize that GSK-3 inhibition may improve cardiac functioning 
and insulin signaling in obese and insulin resistant animals.  
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1.8.3 Aims 
The aims of the present study were to determine whether: 
i) myocardial GSK-3 protein and its substrate proteins are dysregulated in 
obesity and insulin resistance, 
ii)  a specific GSK-3 inhibitor can prevent or improve the cardiovascular 
pathology found in obese and insulin resistant animals. 
 
1.8.4 Objectives 
Our objectives were to correlate the alterations in expression and activation of  
GSK-3 protein in a well characterised rat model of obesity coupled to insulin 
resistance with: 
i) myocardial contractile dysfunction and an inability of hearts to withstand 
ischemia/reperfusion, 
ii)  the activation and expression of PLM and SERCA-2a in the SR 
iii)  the activation of intermediates (IRS-1, IRS-2 and PKB/Akt) that lie upstream 
in the activation pathway of GSK-3. 
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CHAPTER 2 
MATERIALS AND METHODS 
 
2.1 Materials 
The reagents used in the current study were bought from different companies such 
as Merck NT laboratory supplies (PTY, LTD) (NaCl, KCl, CaCl2, KH2PO4, NaHCO3, 
MgSO4, NaSO4, d-glucose, Na
+ pyrophosphate, Folin Ciocalteus (Folin C), sodium 
dodecyl sulphate (SDS), tris (hydroxylmethyl) aminomethane, acrylamide), Sigma-
Aldrich Life Science (ammonium persulfate (APS), pyruvate, mecarpto-ethanol, 
N,N,N,N,-tetramethylethylenediamine (TEMED), ponceau red, 
phenylmethylsulphonyl fluoride (PMSF), triton-X-100), Millipore, (Millipore 
Immobilon-p Polyvinyledene Fluoride (PVDF) microporous membrane and Linco 
Insulin enzyme linked immunosorbent assay (ELISA) kit), Roche Diagnostics, 
(bovine serum albumin (BSA)), Amersham Biosciences, (enhanced 
chemiluminescence (ECL) Western blotting detection reagents, anti-rabbit Ig, 
horseradish peroxidase linked whole secondary antibody), Santa Cruz Biotechnology 
Inc., (SERCA-2a primary antibody), Cell Signaling technology, (IRS-1, IRS-2, GSK-3, 
PKB/Akt, PLM and β-Tubulin primary antibodies) and Bayer-Bayer (Euthanaze). 
 
 
 
 
 
 
 
51 
 
2.2 Methods 
2.2.1 Animals 
Age and weight matched male Wistar rats (animals) were used in the present study. 
At 4 weeks after birth, rats were weaned and placed on ad libitum diet i.e. free 
access to food (standard rat chow) and water. Rats were housed in cages (3 per 
cage) at constant environment of 22oC temperature, 40% humidity and 12 hour 
artificial day/night cycle in the University of Stellenbosch Central Research facility. 
Throughout the study, the revised South African National Standard for the care and 
use of laboratory animals for scientific purposes was followed (SABS, SANS 10386, 
2008). This study was approved by the Ethics committee of Stellenbosch University, 
Faculty of Health Science. 
 
2.2.2 Classification and selection of study groups 
Animals weighing between 160 and 180g were randomly selected and grouped into 
control and diet induced obese (DIO) groups. Controls were fed a normal rat chow 
diet supplying ~380 kJ of energy per day, while DIOs were fed a rat-chow diet 
supplemented with sucrose and condensed milk (~575 kJ energy per day) for a 
period of either 8 or 16 weeks (Table 2.1). The total number of rats used throughout 
the study was 80 and were divided into two groups of 40 controls and 40 DIOs 
(figure 2.1). These two groups were further subdivided into two subgroups of either 
20 controls/DIO and 20 controls/DIO plus GSK-3 inhibitor (figure 2.1). 
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Figure 2.1: Classification of animals into groups. DIO, diet induced obese; GSK-3, 
glycogen synthase kinase-3. 
 
Table 2.1: Diet composition (Controls and DIOs)      
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2.2.3 Treatment with GSK-3 inhibitor 
A GSK-3 inhibitor from Chirone, CHIR118637 (CT20026) was used in the current 
study. Chirone (CHIR118637) inhibitors are ATP competitive inhibitors and have 
been shown to be specific and to target both GSK-3α/β isoforms (Cline et al. 2002; 
Meijer et al. 2004). An amount of the inhibitor was weighed into each well of an ice 
cube container. 1 ml liquid jelly, made up of 2.5g Gelatin, 5g Jelly in 50 ml of water, 
was pipetted into each inhibitor containing wells, mixed thoroughly and allowed to 
solidify. Each rat (weighing about 300g) was given one jelly block according to its 
weight, two times per day (in the morning and afternoon) for four weeks (from week 
12-16 of the diet period). The final dose was 30 mg/kg/day. 
 
Following four weeks treatment, rats were anesthetized by intra-peritoneal injection 
of 160 mg/kg pentobarbitone sodium (Euthanaze), weighed and blood glucose 
concentration determined using a commercial glucometer. Hearts were then excised, 
weighed and freeze clamped in liquid nitrogen. Blood was collected into eppendorf 
tubes, allowed to clot on ice and centrifuged at 15000 revolutions per minute (rpm) 
for 15 minutes. The resultant plasma was then transferred into new eppendorfs and 
both freeze clamped hearts and plasma were stored at -80oC for later use. In 
addition, the intra-peritoneal fat mass and tibial lengths were measured. Protein 
expression and the SERCA-2a activity were then determined using the stored 
hearts. Results obtained after the treatment were then compared with the age-
matched untreated animals. 
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2.3 Experimental procedures 
2.3.1 Western blot  
2.3.1.1 Lysate preparation (GSK-3, PKB/Akt, IRS-1/2 and SERCA-2a) 
Both control and DIO animals were anesthetized with sodium pentobarbitone 
(Euthanaze). Hearts were then quickly excised, the atria removed and the ventricles 
rinsed with Krebs-Heinseleit (KH) buffer and freeze clamped in liquid nitrogen. 
Tissue stored in liquid nitrogen was homogenized in ice-cold lysis buffer (containing 
20 mM Tris-HCl (pH 7.5), 1 mM EGTA, 1 mM EDTA, 150 mM NaCl, 1 mM Na2VO3, 1 
mM β-glycerophosphate, 2.5 mM sodium-pyrophosphate, 0.3 mM PMSF, 1% (v/v) 
Triton X-100, 10 µg/ml leupeptin and 10 µg/ml aprotonin) with a polytron PT-10 
homogenizer (2 x 4 seconds at setting 4). Following homogenization, samples were 
incubated on ice for 10 minutes and centrifuged in a microfuge at 4oC for 15 minutes 
at 14o000 rpm. The resultant supernatants were transferred into new tubes to 
determine the protein content using the Bradford method (section 2.3.1.3). 
 
2.3.1.2 PLM lysate preparation 
Sarcoplasmic reticulum membranes were semi-purified using the method described 
in section 2.3.2.1. The protein content of the resultant semi-purified membrane 
samples was determined using Bradford method (section 2.3.1.3). Lysis buffer was 
added in order to dilute all samples to equal protein concentration. Then 3x Laemmli 
sample buffer with mercaptoethanol was also added. And the samples were 
incubated for 30 minutes at 37oC and frozen for later use. 
 
 
 
55 
 
2.3.1.3 Bradford protein determination  
Bradford protein determination method was used to determine the protein content of 
tissue lysates (Bradford 1976). Protein standards made up of a diluted bovine serum 
albumin (BSA) solution, that contained protein concentration of 1-20 µg in a volume 
of 100µl was pipetted into test tubes (duplicates). The volume pipetted into test tubes 
was (µl): 10, 20, 40, 60 and 80, then dH2O was added into each tube to make a final 
volume of 100µl. 900µl of Bradford reagent (diluted 1:5) was also added, samples 
vortexed and incubated for 15-30 minutes. The absorbance values were measured 
using a spectrophotometer at 595 nm and the standard curve was plotted to 
determine the protein content of the unknown samples.  
 
The samples (supernatants) from the above (section 2.3.1.1) were diluted 1:10 with 
dH2O to dilute all detergents such as Triton-X present, which may interfere with the 
experiment. 5µl of each diluted sample (duplicates) was further diluted with 95µl of 
dH2O to make a total volume of 100µl and 900µl Bradford reagent was added. All 
samples were vortexed thoroughly and incubated at room temperature for 15-30 
minutes. The absorbance was measured with a spectrophotometer at 595 nm and 
the protein content was determined using the above mentioned standard curve. The 
standard curve generated saturates at ~20µg protein concentration per sample, 
therefore the necessary amount of samples were calculated and pipetted into 
Eppendorf tubes. Lysis buffer was added in order to dilute all samples to equal 
protein concentration. Then 3x Laemmli sample buffer with mercaptoethanol was 
also added. The samples were boiled for 5 minutes and stored at -20oC for later use. 
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2.3.1.4 Immunoblotting 
2.3.1.4.1 Loading and separation of proteins 
Following Bradford method, lysates were boiled for 5 minutes (excluding PLM lysates 
which were incubated at 37oC for 30 min), centrifuged and proteins (20-120µg) were 
separated by sodium dodecyl sulphate polyacrylamide gel electrophoresis (SDS-
PAGE) using the standard BIO-RAD Mini-Protein III system. Throughout the study, 
7.5% and 12% resolving gels were used, depending on the size of the protein and 
4% stacking gel on top (table 2.2). The GSK-3, PKB/Akt and PLM proteins were 
separated with a 12% gel, while IRS-1, IRS-2 and SERCA-2a were separated with a 
7.5% gel (table 2.3). The samples and molecular weight marker were loaded into the 
gel and the running buffer containing, 250mM Tris, 192mM glycine and 1% sodium 
dodecyl sulphate (SDS) was added, followed by electrophoresis. The gels were ran 
with 100 volts (V) and 200 milliampere (mA) for 10 minutes followed by 200V and 200 
mA for 65 minutes. The molecular weight marker was used to locate each protein 
separated according to their molecular weights. 
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Table 2.2: Gel composition. Tris-HCl, trisaminomethane pH set with hydrochloric 
acid; SDS, sodium dodecyl sulphate; APS, ammonium persulfate; TEMED, 
tetramethylethylenediamine. 
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2.3.1.4.2 Transfer of proteins 
Following the separation technique, proteins were transferred (200V and 200mA) 
into a polyvinylidene flouride (PVDF) membrane using the electrotransfer system 
with a transfer buffer containing 25mM Tris-HCl, 192mM glycine and methanol (20% 
v/v) for 1 hour. After transfer, the membranes were washed with methanol for 30 
seconds and left to dry for 15 minutes. These membranes were then stained with the 
reversible stain, Ponceau red to visualize the proteins and confirm if transferred 
satisfactorily.  
 
The membranes were then washed with tris buffered saline-tween-20 (0.1%) (TBS-
tween) to remove staining and the membrane blocked by incubating in TBS-tween or 
TBS-tween containing 5% fat free milk powder for ~1.5 hour. After ~1.5 hour, the 
membranes were washed with TBS-tween, incubated in the primary (1o) antibody 
that specifically recognize total or phosphorylated proteins and placed on a belly 
dancer, at 4oC overnight. The primary antibodies used in the current study were total 
and phosphorylated GSK-3(α/β), total and phosphorylated PKB/Akt-α, total and 
phosphorylated PLM, total SERCA-2a, total IRS-1 and total IRS-2. These primary 
antibodies were either diluted with TBS-tween or 5% fat free milk in TBS-tween 
which varies according to the individual protein (table 2.3). 
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2.3.1.5 Secondary (2o) antibody and Immunodetection 
The following day, the membranes were washed with TBS-tween and incubated in 
diluted secondary antibody for 1 hour at room temperature. The horseradish 
peroxidise-labelled secondary antibody (antirabbit for GSK-3, PKB/Akt, IRS-1/2 and 
PLM; or donkey-antigoat for SERCA-2a) was either diluted with TBS-tween or TBS 
tween containing 5% fat free milk powder (table 2.3). After an hour, the membranes 
were washed thoroughly with TBS-tween, covered with enhanced 
chemiluminescence (ECL) detection reagents (Amersham, Life Sciences) in the dark 
room and exposed to an autoradiography film (Hyperfilm ECL, RPN 2103-
Amersham, Life Science) to detect light emission. The duration at which individual 
proteins were exposed differs from one to another (table 2.3). 
 
2.3.1.6 Densitometry 
Following exposure, the films were scanned and analysed with densitometry (UN-
SCAN-IT, Silk Scientific Inc., Orema, Utah, USA). The protein values were then 
determined and expressed as the total and phosphorylated proteins. 
 
2.3.1.7 Equal loading 
To confirm if the proteins were equally loaded, all blots were stripped by washing 
them twice with distilled water (dH2O) for 5 minutes each and incubated for another 5 
minutes in 0.2M NaOH on the belly dancer at room temperature. After 5 minutes, 
membranes were washed twice again with dH2O for 5 minutes each, blocked with 
TBS tween containing 5% fat free milk powder for ~1.5 hour and incubated with β-
tubulin (Table 2.3) primary antibody overnight. Membranes were then washed, 
incubated with secondary antibody, exposed and developed as above. Bands from 
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the β-tubulin blott should have equal intensity and changes seen from the stripped 
blott should not be present in the β-tubulin blott (figure 2.3). 
A. Total IRS-1 
 
B. β-Tubulin 
 
Figure 2.2: Total IRS-1 and β-Tubulin. Shown are the A. IRS-1 and B. β-Tubulin 
blots, as an example confirming equal loading. 
 
Table 2.3: Shown is the gel percentage, protein concentration, primary (1o) and 
secondary (2o) antibodies and the exposure time for individual protein. TBS, tris-
buffered saline; MW, molecular weight; KDa, Kilo Daltons. 
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2.3.2 Enzyme Assays 
2.3.2.1 Preparation of semi-purified sarcoplasmic reticulum membranes 
Sarcoplasmic reticulum membranes were semi-purified using the method described 
by Feher and Davis 1991. After anesthesia, hearts were excised and cut finely with 
scissors in ice cold 0.9% NaCl and rinsed to remove all traces of blood. One heart 
was homogenized in 5 ml ice cold KCl- imidazole isolation buffer (1M KCl, 10mM 
imidazole, pH 7) with a Polytron (PT 10) homogenizer, 2 x 7 seconds at setting 6. 
The resultant homogenate was centrifuged for 20 minutes at 10 000xg using a 
Sorval SS 34 Rotor. The supernatant was discarded and the resultant pellet 
rehomogenized in 5 ml isolation buffer as described above. The homogenate was 
recentrifuged at 6 000xg for 20 minutes and pellet was discarded. Supernatant was 
centrifuged with a Beckman ultra-centrifuge at 27 000xg for 45 minutes. The 
resultant supernatant and fluffy layer on top of the pellet were transferred into a 
Potter-Elvehjem homogenizer and homogenized thoroughly. 
 
2.3.2.2 Ca2+-ATPase activity  
Ca2+-ATPase activity was defined as the difference in the amount of Pi produced in 
the absence or presence of 3mM CaCl2 in a reaction medium containing 100mM 
KCl, 50mM Imidazole-HCl (pH 7.5), 5mM NaN3, 3mM EGTA, 5mM MgCl2, 2mM K
+-
oxalate and 3mM ATP at pH 7.5. A volume of 900µl of the reaction medium (with or 
without CaCl2) was added into 50 µl membrane fraction and incubated at 37
oC for 5 
minutes. The reaction was initiated by adding 100µl ATP, incubated further for 10 
minutes and stopped by adding 1 ml 10% tri-chloroacetic acid (TCA) at set time 
intervals. The reaction mixture was centrifuged at 4 000rpm for 15 minutes to remove 
chlorate precipitate. 
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To determine the amount of inorganic phosphate (Pi) liberated, 1 ml 5N-H2SO4 and 1 
ml Ammonium-molibdate (2.5g/100ml) were added into a 1 ml aliquot of the 
supernatant, vortexed thoroughly and incubated for 10 minutes. The complex formed 
was reduced by adding 100 µl reducing agent (RA) containing 0.239mM 1 Amino-2-
Naphthol-4-Sulphonic acid, 0.19mM Sodium bisulphite (Na2S2O5), 0.126mM Sodium 
Sulphite (Fiske and Subbarow 1925) and 6.9ml distilled water (dH2O), vortexed and 
incubated for 10 minutes. Colour development was determined 
spectrophotometrically at 660nm. 
 
2.3.2.3 Insulin enzyme linked immunosorbent assay (ELISA) 
Insulin levels were determined from the previously stored plasma using an ELISA kit 
(Millipore). This assay is based on binding of insulin molecules from the samples to 
the wells of a microtiter plate, coated by a pre-titered amount of monoclonal mouse 
anti rat insulin antibodies and the binding of biotinylated polyclonal antibodies to the 
bound insulin (Millipore 2008). The 96 wells on the microtiter plate were divided into 
blanks (NSB) (x2), standards (x12), quality controls (QC) (x4) and samples (x78) and 
were all repeatedly washed three times with 300µl diluted (10X) wash buffer. Then 
10µl assay buffer was added onto the non specific binding (NSB) wells. Followed by 
addition of 10µl Matrix solution to the NSB, standard and control wells. 10µl rat 
insulin standards were then added (duplicates) in order of ascending concentration. 
10µl QC1 and QC2 were also added in to the appropriate wells in duplicates. In 
sample wells, 10µl sample was added sequentially in duplicates.  
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80µl Detection antibody was added into all wells, plates covered and incubated for 
two hours on an orbital microtiter plate shaker (400-500rpm) at room temperature. 
After 2 hours, the solution from the plate was decanted, plate tapped and washed 3 
times with 10x diluted wash buffer (300µl). 100µl enzyme solution was added into 
each well, plate covered and incubated on shaker for 30 minutes at room 
temperature. Thereafter, the plate sealer was removed, solution decanted and the 
wells washed 6 times with 10x diluted wash buffer (300µl for each well per wash). 
100µl substrate solution was then added into each well, plate covered and incubated 
on shaker for 15 minutes. When the blue colour had developed, 100µl stop solution 
was added and the plates shaked by hand to mix the solution (blue turned to yellow 
color). The absorbance was then read at 450 nm and 590 nm in a plate reader and 
insulin concentrations were calculated. Insulin sensitivity was also determined using 
homeostasis model assessment (HOMA) index, calculated using the equation 
([Glucose] x [Insulin])/22.5. 
 
2.3.3 Lowry Protein determination method 
50µl homogenate from the above Ca2+-ATPase activity assay (section 2.3.2.2) was 
pipetted into glass tubes, 1ml 10% Tri-chloroacetic acid (TCA) added and the 
mixture incubated on ice for 30 minutes or overnight at 4oC to precipitate all proteins. 
Samples were then centrifuged at 2500rpm for 15 minutes at 4oC and the resultant 
supernatant was carefully decanted and discarded. 500µl 1N NaOH was added and 
samples were heated in a water bath at 70oC to dissolve the precipitate. 500µl dH2O 
was then added to dilute the samples 1:1 to give a 0.5N NaOH solution and vortexed 
thoroughly. 50µl protein sample, standards (3 different BSA solutions with known 
protein concentration dissolved in 0.5N NaOH) and 0.5N NaOH (blank) was pipetted 
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into lucham tubes in triplicates. 1 ml Na+K+-Tartrate-CuSO4 was added into the 50 µl 
samples, standards and blank from above at set time intervals and were vortexed 
and incubated at room temperature for 10 minutes. After 10 minutes, 0.1 ml of a 1:3 
dilution of Folin Ciocalteus (Folin C) reagent was added at the same set time 
intervals, vortexed and incubated for 30 minutes. After 30 minutes, OD values were 
determined using a spectrophotometer at 750nm starting with the blank, standards 
and then samples. A standard curve was generated and the protein content of the 
samples was determined. 
 
2.3.4 Heart Perfusion 
Rats were anesthetized by intra-peritoneal injection of 160 mg/kg euthanaze. After 
deep anesthesia, as determined by a foot pinch, hearts were quickly excised and 
arrested in ice cold Krebs-Henseleit (KH) buffer containing 119 mM NaCl, 25 mM 
NaHCO
3
, 4.7 mM KCl, 1.2 mM KH
2
PO
4
, 0.59 mM MgSO
4
·7H
2
O, 0.59 mM Na
2
SO
4
, 
1.25 mM CaCl
2
·2H
2
O and 11 mM glucose. Isolated hearts were then rapidly 
mounted on the aortic cannula and retrogradely perfused (Langendorff mode) at 
37oC with the KH buffer gassed with 95% O2 and 5% CO2 to maintain the pH at 7.4. 
Thermistor probe was inserted into the right coronary sinus to monitor the myocardial 
temperature. To monitor the function of the heart, a water (dH2O) filled latex balloon 
was inserted into the left ventricle and inflated to establish a baseline pressure 
(diastolic) of 4-10 mmHg. The balloon was then connected to a pressure transducer 
(Mantaflex) to relay the pressure changes in the left ventricle via the amplifier to the 
powerlab/P200 (AD Instrument) which digitally displays the results on a computer.  
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2.3.4.1 Perfusion protocol 
To determine functional perfomance, the hearts were stabilized for 30 minutes and 
subjected to low flow ischemia with a coronary flow rate of 0.2 ml/min for 25 minutes 
which then was followed by 30 minutes of reperfusion, figure 2.2. Throughout the 
experiment, changes in diastolic and systolic pressure were monitored. Coronary 
flow rate, heart rate (HR), time to onset of ischemic contracture (TOIC), peak 
contracture diastolic pressure (PCDP) and end ischemic diastolic pressure (EIDP) 
were also recorded. The rate pressure product (RPP) was then calculated from heart 
rate and the developed pressure. Baseline results were measured during 
stabilization. 
 
Figure 2.3: Standard perfusion protocol. Shown is the time at which the perfusion 
was started, duration of low flow ischemia (LFI), coronary flow rate (0.2 ml/min) and 
reperfusion period. 
 
2.4 Statistical analysis 
Results were statistically compared using Microsoft GraphPad Prism (version 5.0). 
Student‘s t-test was used to compare two variables, while one or two way analysis of 
variance (ANOVA) with Bonferroni post hoc test was used when comparing more 
than two variables. All values are expressed as the mean ± standard error of the 
mean (SEM) and p-value of less than 0.05 was considered statistically significant. 
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CHAPTER 3 
RESULTS 
3.1 8 weeks data (Baseline) 
3.1.1 Biometric parameters 
Following 8 weeks on diet, DIO animals were significantly bigger than control 
animals (*p<0.0001) (figure 3.1). This was associated with increased intra-peritoneal 
(IP) fat in DIO animals (**p<0.0001) (figure 3.2). 
Figure 3.1: Body weight (BW). Shown is the body weight measured in grams (g) of 
diet induced obese (DIO) and control animals (8 weeks). 
 
*p<0.0001 
n= 6 
 
 
* 
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Figure 3.2: Intra-peritoneal (IP) fat: Shown is the IP fat mass measured in grams (g) 
of diet induced obese (DIO) and control animals (8 weeks). 
 
 
 
 
 
 
 
 
 
 
**p<0.0001 
n= 6 
 
** 
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3.1.2 Expression and phosphorylation of proteins (8 weeks) 
3.1.2.1 GSK-3 protein 
3.1.2.1.1 Total GSK-3 
Following eight weeks on diet there was no significant difference in total GSK-3 
protein expression between controls and DIO animals (figure 3.3). However, there 
was a trend towards increase in DIO animals. 
 
 
Figure 3.3: Total Glycogen synthase kinase 3 (GSK-3). Shown is the Western blot 
for total GSK-3 protein and fold stimulation (compared to the first loaded control that 
was assigned a value of 1) graph comparing controls and diet induced obese (DIO) 
animals. 
 
Controls DIO 
n= 6 
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3.1.2.1.2 Phosphorylated GSK-3α (Alpha) 
After eight weeks on diet, there was no significant difference in GSK-3α 
phosphorylation when controls and DIO animals were compared (figure 3.4). In 
addition, there was also no significant difference in phosphorylated (alpha)/total ratio 
between these two groups (figure 3.5). 
 
 
 
Figure 3.4: GSK-3α (Alpha) phosphorylation. Shown is the Western blot 
representing phosphorylated both GSK-3α and GSK-3β as well as a graph showing 
GSK-3α fold stimulation (compared to the first loaded control that was assigned a 
value of 1) comparing diet induced obese (DIO) and control animals. 
 
Controls DIO 
Alpha 
Beta 
n= 6 
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Figure 3.5: Phospho (Alpha)/total ratios of GSK-3 protein. Shown are the alpha 
phospho/total ratio of both control and DIO animals. 
 
 
 
 
 
 
 
 
 
 
 
n= 6 
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3.1.2.1.3 Phosphorylated GSK-3 Beta 
After eight weeks of feeding, there was no significant difference in phosphorylation of 
GSK-3β between controls and DIO animals (figure 3.6). In addition, there was also 
no significant difference in P/T ratio of GSK-3β (figure 3.7). 
 
Figure 3.6: Beta phosphorylation of Glycogen synthase kinase 3 (GSK-3β). Shown 
is the GSK-3β fold stimulation (compared to the first loaded control that was 
assigned a value of 1) comparing diet induced obese (DIO) and control animals. 
 
 
 
 
 
 
n= 6 
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Figure 3.7: Phospho (Beta)/total ratios of GSK-3 protein. Shown are the beta 
phospho/total ratios of both control and DIO animals. 
 
 
 
 
 
 
 
 
 
 
 
 
 
n= 6 
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3.1.2.2 PKB/Akt protein 
3.1.2.2.1 Total PKB/Akt protein 
Following eight weeks on diet, there was no significant difference in expression of 
total PKB/Akt when comparing controls and DIO animals (figure 3.8). 
 
  
Figure 3.8: Protein kinase B/Akt (PKB/Akt). Shown is the Western blot representing 
total PKB/Akt as well as a graph showing its fold stimulation (compared to the first 
loaded control that was assigned a value of 1) in controls and diet induced obese 
(DIO) animals. 
 
 
 
DIO Controls 
n= 6 
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3.1.2.2.2 Phosphorylated PKB/Akt protein 
Following eight weeks of diet, there was no significant difference in PKB/Akt 
phosphorylation when controls and DIO animals were compared (figure 3.9). There 
was also no significant difference in phospho/total ratios of PKB/Akt between control 
and DIO animals (figure 3.10). 
 
 
Figure 3.9: Protein kinase B/Akt (PKB/Akt) phosphorylation. Shown is the Western 
blot representing PKB/Akt phosphorylation as well as a graph showing its fold 
stimulation (compared to the first loaded control that was assigned a value of 1) in 
controls and diet induced obese (DIO) animals. 
 
DIO Controls 
n= 6 
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Figure 3.10: Protein kinase B/Akt (PKB/Akt). Shown are the phospho/total ratios of 
both control and DIO animals. 
 
 
 
 
 
 
 
 
 
 
 
 
n= 6 
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3.1.2.3 Total IRS-1 protein 
After eight weeks on diet, IRS-1 protein was significantly downregulated in DIO 
animals when compared to their age matched controls (*p= 0.0002) (figure 3.11). 
 
 
 
Figure 3.11: Insulin receptor substrate-1 (IRS-1). Shown is the Western blot 
representing total IRS-1 expression and its fold stimulation (compared to the first 
loaded control that was assigned a value of 1) graph comparing controls and DIO 
animals. 
 
 
 
 
 
DIO Controls 
* 
*p= 0.0002 
n= 4-6 
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3.1.2.4 Total IRS-2 protein 
Following eight weeks on diet, there was no significant difference in expression of 
IRS-2 protein when comparing controls and DIO animals (figure 3.12). 
 
 
 
Figure 3.12: Insulin receptor substrate-2 (IRS-2). Shown is the Western blot 
representing total IRS-2 expression and its fold stimulation (compared to the first 
loaded control that was assigned a value of 1) graph comparing controls and DIO 
animals. 
 
 
 
 
DIO Controls 
n= 4-6 
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3.1.2.5 Total SERCA-2a protein 
After eight weeks on diet, DIO animals had a decreased SERCA-2a expression as 
compared to the age matched controls (*p= 0.0418) (figure 3.13). 
 
 
 
Figure 3.13: Total SERCA-2a. Shown is the Western blot representing total SERCA-
2a expression as well as fold stimulation (compared to the first loaded control that 
was assigned a value of 1) graph comparing controls and DIO animals. 
 
 
 
 
 
DIO Controls 
* 
*p= 0.0418 
n= 4-6 
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3.2 Sixteen (16) weeks data (Baseline) 
3.2.1 Biometric parameters 
After 16 weeks on diet, the DIO animals were significantly bigger than their age 
matched control animals (*p=0.0009) (figure 3.14). This increased body weight was 
also associated with increased IP fat in DIO animals (*p=0.0002) (figure 3.15). 
 
 
Figure 3.14: Body weight (BW). Shown is the body weight measured in grams (g) of 
diet induced obese (DIO) and control animals (16 weeks). 
 
*p= 0.0009 
n= 6-9 
 
 
* 
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Figure 3.15: Intra-peritoneal (IP) fat. Shown is the IP fat mass measured in grams 
(g) of diet induced obese (DIO) and control animals (16 weeks). 
 
 
 
 
 
 
 
 
 
 
 
*p= 0.0002 
 n= 6-9 
 
 
* 
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3.2.2 Expression and phosphorylation of proteins (16 weeks) 
3.2.2.1 GSK-3 protein 
3.2.2.1.1 Total GSK-3  
Following 16 weeks on diet, there was no significant difference in total GSK-3 
expression when DIO animals were compared to their age matched controls (figure- 
3.16). However, there was a tendency towards elevated expression. 
 
 
 
Figure 3.16: GSK-3 protein. Shown is the Western blot representing total GSK-3 
expression as well as its fold stimulation (compared to the first loaded control that 
was assigned a value of 1) graph comparing controls and diet induced obese (DIO) 
animals. 
DIO Controls 
n= 6-9 
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3.2.2.1.2 Phosphorylated GSK-3α 
After 16 weeks of diet, there was no significant difference in GSK-3α phosphorylation 
between controls and DIO animals (figure 3.17). In addition, there was also no 
significant difference in GSK-3α phospho/total (P/T) ratio between controls and DIO 
animals (figure 3.18). 
 
 
 
 
Figure 3.17: Phosphorylated GSK-3α protein. Shown is the Western blot 
representing both GSK-3α and GSK-3β phosphorylation. In addition, shown is the 
fold stimulation (compared to the first loaded control that was assigned a value of 1) 
graph of GSK-3α comparing controls and DIO animals. 
n= 6-9 
DIO Controls 
Alpha 
Beta 
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Figure 3.18: GSK-3 P/T ratio. Shown are the alpha phospho/total (P/T) ratios of both 
control and diet induced obese (DIO) animals. 
 
 
 
 
 
 
 
 
 
 
 
 
n= 6-9 
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3.2.2.1.3 Phosphorylated GSK-3β 
Following 16 weeks on diet, there was no significant difference in phosphorylated 
GSK-3β between controls and DIO animals (figure 3.19). There was also no 
significant difference in P/T ratio of GSK-3β between these two groups (figure 3.20). 
 
Figure 3.19: Beta phosphorylation of Glycogen synthase kinase 3 (GSK-3β). Shown 
is the fold stimulation (compared to the first loaded control that was assigned a value 
of 1) graph of phosphorylated GSK-3β comparing controls and DIO animals. 
 
 
n= 6-9 
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Figure 3.20: GSK-3 P/T ratio. Shown are the beta phospho/total ratios of both 
control and DIO animals. 
 
 
 
 
 
 
 
 
 
 
 
 
n= 6-9 
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3.2.2.2 Protein kinase B (PKB/Akt) protein 
3.2.2.2.1 Total Protein kinase B (PKB/Akt) 
Following 16 weeks on diet, total PKB/Akt expression was significantly down 
regulated in DIO animals when compared to their age matched controls (*p= 0.0425) 
(figure 3.21).  
 
 
 
 
Figure 3.21: Protein kinase B/Akt (PKB/Akt). Shown is the Western blot representing 
total PKB/Akt as well as a graph comparing fold stimulation (compared to the first 
loaded control that was assigned a value of 1) between controls and diet induced 
obese (DIO) animals. 
 
DIO Controls 
*p= 0.0425 
n= 6-9 
* 
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3.2.2.2.2 Phosphorylated Protein kinase B (PKB/Akt) 
Following 16 weeks of diet, there was no significant difference in PKB/Akt 
phosphorylation when controls and DIO animals were compared (figure 3.22). There 
was also no significant difference in phospho/total ratios of PKB/Akt between control 
and DIO animals (figure 3.23). 
 
 
 
 
Figure 3.22: Protein kinase B/Akt (PKB/Akt) phosphorylation. Shown is the Western 
blot representing PKB/Akt phosphorylation as well as a graph showing its fold 
stimulation (compared to the first loaded control that was assigned a value of 1) in 
controls and diet induced obese (DIO) animals. 
 
 
n= 6-9 
DIO Controls 
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Figure 3.23: PKB/Akt (P/T ratio). Shown are the phospho/total ratios of both control 
and diet induced obese (DIO) animals. 
 
 
 
 
 
 
 
 
 
 
 
 
 
n= 6-9 
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3.2.2.3 Total IRS-1 expression 
After 16 weeks on diet, total IRS-1 protein was significantly downregulated in DIO 
animals as compared to their age matched controls (*p=0.0001) (figure 3.24). 
 
 
 
 
Figure 3.24: Total IRS-1 protein. Shown is the Western blot representing total IRS-1 
expression as well as a graph showing its fold stimulation (compared to the first 
loaded control that was assigned a value of 1) in controls and diet induced obese 
(DIO) animals. 
 
 
 
 
DIO Controls 
* 
*p= 0.0001 
n= 6-9 
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3.2.2.4 Total IRS-2 expression 
Following 16 weeks on diet, IRS-2 protein was significantly downregulated in DIO 
animals as compared to the age matched control animals (*p=0.022) (figure 3.25). 
 
 
 
 
 
Figure 3.25: Total IRS-2 protein. Shown is the Western blot representing total IRS-2 
expression as well as a graph showing its fold stimulation (compared to the first 
loaded control that was assigned a value of 1) in controls and diet induced obese 
(DIO) animals. 
 
 
 
DIO Controls 
* 
*P= 0.022 
n= 6-9 
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3.2.2.5 Total SERCA-2a expression 
After 16 weeks on diet, DIO animals presented with decreased SERCA-2a 
expression as compared to the age matched controls (*p<0.0001) (figure 3.26). 
 
 
 
 
Figure 3.26: Total SERCA-2a protein expression. Shown is the Western blot 
representing total SERCA-2a expression as well as a graph showing its fold 
stimulation (compared to the first loaded control that was assigned a value of 1) in 
controls and diet induced obese (DIO) animals. 
 
 
 
DIO Controls 
* 
*P<0.0001 
n= 6-9 
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3.2.2.6 Phospholamban (PLM) protein 
3.2.2.6.1 Total Phospholamban (PLM) 
Following 16 weeks on diet, total PLM protein was significantly upregulated in DIO 
animals as compared to the age matched controls (*p= 0.0033) (figure 3.27).  
 
 
 
 
Figure 3.27: Total PLM protein. Shown is the Western blot representing total PLM 
protein expression as well as a graph showing its fold stimulation (compared to the 
first loaded control that was assigned a value of 1) in controls and diet induced 
obese (DIO) animals. 
 
 
 
DIO Controls 
* 
*P= 0.0033 
n= 6-9 
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3.2.2.6.2 Phosphorylated PLM 
After 16 weeks of diet, the PLM protein was significantly less phosphorylated in DIO 
animals as compared to the age matched controls (*p= 0.0095) (figure 3.28). In 
addition, the P/T ratios of PLM were significantly smaller in DIO animals (*p= 0.0018) 
(figure 3.29). 
 
 
 
Figure 3.28: Phosphorylation of Phospholamban (PLM). Shown is the Western blot 
representing PLM phosphorylation as well as a graph showing its fold (compared to 
the first loaded control that was assigned a value of 1) in controls and diet induced 
obese (DIO) animals. 
 
 
*P= 0.0095 
n= 6-9 
* 
DIO Controls 
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Figure 3.29: PLM (P/T ratio). Shown are the phospho/total ratios of both controls 
and DIO animals (*p= 0.0018). 
 
 
 
 
 
 
 
 
 
 
 
 
* 
*P= 0.0018 
n= 6-9 
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3.2.3 Calcium ATPase activity 
After 16 weeks on diet, DIO animals presented with significantly decreased calcium 
ATPase activity as compared to the age matched control animals (*p= 0.0092) 
(figure 3.30). 
 
Figure 3.30: Calcium ATPase activity. Shown are the calcium ATPase activities in 
both controls and DIO animals as determined by the amount of inorganic phosphate 
(Pi) produced. 
 
 
 
 
 
 
*P= 0.0092 
n= 6-9 
* 
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3.2.4 Perfusion 
3.2.4.1 Systolic pressure (SP) 
Following 16 weeks of diet, there was no significant difference in systolic pressure 
(SP) when comparing DIO and control animals at baseline (Figure 3.31A) and during 
reperfusion (figure 3.31B). 
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Figure 3.31: Systolic pressure (SP). Shown is the systolic pressure at baseline (A) 
and during reperfusion (B). 
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3.2.4.2 Diastolic pressure (DP) 
After 16 weeks on diet, there was no significant difference in diastolic pressure (DP) 
when comparing DIOs and control animals at both baseline (figure 3.32A) and 
reperfusion (figure 3.32B).  
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Figure 3.32: Diastolic pressure (DP). Shown is the diastolic pressure at baseline (A) 
and during reperfusion (B). 
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3.2.4.3 Left ventricular developed pressure (LVDevP) 
Following 16 weeks on diet, there was no significant difference in left ventricular 
developed pressure when comparing DIO and control animals at both baseline 
(figure 3.33A) and reperfusion (figure 3.33B). 
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Figure 3.33: Left ventricular developed pressure (LVDevP). Shown is the left 
ventricular developed pressure at baseline (A) and during reperfusion (B). 
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3.2.4.4 Heart rate (HR) 
After 16 weeks on diet, DIO animals had a significantly slower heart rate when 
compared to the age matched controls at baseline (*p<0.0001) (figure 3.34A). 
However, there was no significant difference in heart rates when controls and DIO 
animals were compared at reperfusion (figure 3.34B). 
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Figure 3.34: Heart rate (HR). Shown is the heart rate at baseline (A) and during 
reperfusion (B). 
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3.2.4.5 Rate pressure product (RPP) 
Following 16 weeks on diet, DIO animals had significantly decreased rate pressure 
product when compared to control animals at baseline (*p<0.0001) (figure 3.35A). 
However, there was no significant difference between controls and DIO animals at 
reperfusion (figure 3.35B). 
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B. Rate pressure product at reperfusion 
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Figure 3.35: Rate pressure product (RPP). Shown is the RPP of both controls and 
DIO animals at baseline (A) and during reperfusion (B). 
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3.2.4.6 Low flow ischemia 
During low flow ischemia (0.2 ml/min), DIO animals had a longer time to onset of 
ischemic contracture when compared to the age matched controls (*p= 0.0001) 
(figure 3.36). However, there was no significant difference in time to peak of 
contracture (TPC) (figure 3.37A), peak contracture diastolic pressure (PCDP) (figure 
3.37B) and end ischemic diastolic pressure (EIDP) (figure 3.37C). 
 
A. Time to onset of ischemic contracture (TOIC) 
 
Figure 3.36: Time to onset of ischemic contracture (TOIC). Shown is the TOIC of 
both controls and DIO animals during low flow ischemia (25 min). 
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A. Time to peak of contracture (TPC) 
 
B. Peak contracture diastolic pressure (PCDP) 
 
 
Figure 3.37A-B: Time to peak of contracture (A), Peak contracture diastolic pressure 
(B). Shown is the TPC and PCDP of both controls and DIO animals.  
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C. End ischemic diastolic pressures (EIDP) 
 
Figure 3.37C: Time to peak of contracture (A), Peak contracture diastolic pressure 
(B) and End ischemic diastolic pressures (C). Shown are TPC, PCDP and EIDP of 
both controls and DIO animals. 
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3.2.4.7 Coronary flow rate (CF) 
The rate of coronary flow was also measured at baseline and during reperfusion. 
There was no significant difference in coronary flow rate when DIO and control 
animals were compared (figure 3.38). 
 
Figure 3.38: Coronary flow rates. Shown is the rate of coronary flow at baseline and 
at reperfusion. 
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3.3 Sixteen (16) weeks plus treatment data 
3.3.1The effect of GSK-3 inhibition on biometric and biochemical parameters 
3.3.1.1 Effect on body weight and IP fat mass 
3.3.1.1.1 Body weight (BW) 
Following 16 weeks of diet, untreated DIO animals were significantly bigger than 
untreated controls (**p=0.0001) (figure 3.39). In addition, following 12 weeks of diet 
and the other four weeks on diet plus treatment with GSK-3 inhibitor, treated DIO 
animals were also significantly bigger than treated controls (##p= 0.0002). However, 
when comparing treated and untreated DIO animals, treated DIO animals gained 
less weight than untreated DIOs (#p= 0.0155) (figure 3.39), while the treated controls 
were significantly bigger than untreated control animals (*p= 0.0453) (figure 3.39).  
 
Figure 3.39: Body weight (BW). Shown is the body weight measured in grams (g) of 
treated and untreated diet induced obese (DIO) and control animals after four weeks 
of treatment with GSK-3 inhibitor.  
**p= 0.0001 
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3.3.1.1.2 Intra-peritoneal (IP) fat mass 
The untreated DIO animals had significantly more IP fat mass than untreated 
controls (**p= 0.0002). In addition, following 4 weeks of treatment with GSK-3 
inhibitor, treated DIO animals also had more IP fat than treated controls (##p<0.0001) 
(figure 3.40). However, there was no significant difference in IP fat mass when 
treated and untreated DIO animals were compared as well as between treated and 
untreated control animals (figure 3.40). 
 
Figure 3.40: Intra-peritoneal (IP) fat. Shown is the IP fat mass measured in grams 
(g), of treated and untreated diet induced obese (DIO) and control animals after four 
weeks of treatment with GSK-3 inhibitor. 
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3.3.1.2 Effect on ventricular weight (VW) 
The ventricles from untreated DIO animals were significantly larger than those 
coming from untreated controls (**p= 0.0003). In addition, following four weeks of 
treatment with GSK-3 inhibitor,  treated DIO animals also had larger ventricles than 
treated controls (##p= 0.0140) (figure 3.41). However, when comparing treated and 
untreated DIO animals, the treated DIOs had significantly smaller ventricles than 
untreated DIO animals (
#
p= 0.0166). However, in control animals, treated controls 
had significantly larger ventricles than untreated controls (*p= 0.0072) (figure 3.41). 
 
Figure 3.41: Ventricular weight (VW). Shown are the ventricular weights measured 
in grams (g) of treated and untreated diet induced obese (DIO) and control animals 
after four weeks of treatment with GSK-3 inhibitor. 
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3.3.1.3 Effect on tibia length 
Following 16 weeks on diet, there was no significant difference in tibia length 
between untreated DIOs and untreated controls as well as between treated DIOs 
and treated control animals (figure 3.42). There was also no significant difference in 
tibia length between treated and untreated DIOs as well as between treated and 
untreated control animals (figure 3.42). 
 
Figure 3.42: Tibia length. Shown are the tibia lengths measured in centimetres (cm) 
of treated and untreated diet induced obese (DIO) and control animals after four 
weeks of treatment with GSK-3 inhibitor. 
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3.3.1.4 Ventricular weight/tibia length (VW/TL) ratios 
Following 16 weeks of diet, the VW/TL ratios were significantly higher in untreated 
DIO animals as compared to untreated controls (**p<0.0001) (figure 3.43). In 
addition, after four weeks of treatment with GSK-3 inhibitor,, the treated DIO animals 
also had higher VW/TL ratios than treated controls (##p= 0.0204). However, treated 
DIO animals had significantly lower VW/TL ratios as compared to untreated DIOs  
(
#
p= 0.0206), while treated controls had higher VW/TL ratio than untreated controls 
 (*p= 0.0007) (figure 3.43).  
 
 
Figure 3.43: Ventricular Weight (VW)/Tibia length (TL) ratios. Shown are the VW/TL 
ratios of treated and untreated diet induced obese (DIO) and control animals after 
four weeks of treatment with GSK-3 inhibitor. 
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3.3.1.5 Effect on fasting blood glucose levels 
Following 16 weeks on diet, fasting blood glucose levels were significantly higher in 
untreated DIOs than untreated control animals (*p= 0.0238) (figure 3.44). However, 
following four weeks of treatment with GSK-3 inhibitor, there was no significant 
difference in fasting blood glucose levels when treated DIOs and treated control 
animals were compared, as well as between treated and untreated DIOs, and 
treated and untreated control animals (figure 3.44). 
 
Figure 3.44: Fasting blood glucose levels. Shown are the fasting blood glucose 
levels of treated and untreated diet induced obese (DIO) and control animals after 
four weeks of treatment with GSK-3 inhibitor. 
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3.3.1.6 Effect on fasting plasma insulin levels 
Following 16 weeks on diet, the levels of insulin were significantly higher in untreated 
DIOs than untreated control animals (**p=0.0313). In addition, following four weeks 
of treatment with GSK-3 inhibitor, treated DIOs were also significantly higher than 
treated control animals (##p= 0.0213) (figure 3.45). However, there was no significant 
difference in fasting plasma insulin levels when treated and untreated DIO animals 
were compared, as well as between treated and untreated control animals (figure 
3.45). 
 
Figure 3.45: Fasting plasma insulin levels. Shown are the fasting plasma insulin 
levels of treated and untreated diet induced obese (DIO) and control animals after 
four weeks of treatment with GSK-3 inhibitor. 
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3.3.1.7 Homeostasis model assessment (HOMA) Index 
There was no significant difference in HOMA index between untreated DIOs and 
untreated control animals, as well as between treated DIOs and control animals 
(figure 3.46). There was also no significant difference in HOMA index between 
treated and untreated DIOs as well as between treated and untreated controls 
(3.46). 
 
Figure 3.46: Homeostasis model assessment (HOMA) Index. Shown is the HOMA 
index of treated and untreated diet induced obese (DIO) and control animals after 
four weeks of treatment with GSK-3 inhibitor. 
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3.3.2 Effect of GSK-3 inhibition on protein expression and phosphorylation 
3.3.2.1 Effect on GSK-3 protein  
3.3.2.1.1 Total GSK-3 
Following 16 weeks on diet, there was no significant difference in total GSK-3 when 
untreated DIOs and untreated controls were compared; however, there was a 
tendency towards increase in untreated DIO animals (not shown on the blot below). 
In addition, following the treatment with GSK-3 inhibitor, there was also no significant 
difference between treated DIOs and treated control animals (figure 3.47). There 
was also no significant difference in total GSK-3 protein when treated and untreated 
controls as well as treated and untreated DIOs were compared (figure 3.47). 
 
 
Figure 3.47: Total GSK-3. Shown is one of the Western blots representing total 
GSK-3 expression, as well as a graph showing its fold stimulation (compared to the 
first loaded control that was assigned a value of 1) in controls and diet induced 
obese (DIO) animals. 
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3.3.2.1.2 Effect on GSK-3 phosphorylation 
After 16 weeks on diet, there was no significant difference in GSK-3β 
phosphorylation when untreated DIO animals were compared to untreated controls. 
However, after four weeks of treatment with GSK-3 inhibitor, treated DIO animals 
had less GSK-3 phosphorylation when compared to treated controls (##p= 0.0007) 
(figure 3.48). In addition, GSK-3 was more phosphorylated in treated than untreated 
controls (*p= 0.0008). However, there was no significant difference in GSK-3 
phosphorylation between treated and untreated DIO animals (figure 3.48). GSK-3α 
was not phosphorylated in DIO animals. 
 
 
 
Figure 3.48: GSK-3β phosphorylation. Shown is the Western blot representing total 
GSK-3β phosphorylation, as well as a graph showing its fold stimulation (compared 
to the first loaded control that was assigned a value of 1) in controls and diet induced 
obese (DIO) animals. 
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3.3.2.1.3 Phospho/Total (P/T) ratios of GSK-3 protein 
The P/T (GSK-3β) ratios were significantly lower in untreated DIO animals than 
untreated controls (**p= 0.0489) as well as when treated DIO animals and treated 
controls were compared (##p= 0.0020) (figure 3.49). In addition, treated controls had 
significantly higher P/T ratio than untreated control animals (*p= 0.0025). There was 
no significant difference between treated and untreated DIOs, but there was a trend 
towards increased P/T ratio in treated DIO animals (figure 3.49). 
 
Figure 3.49: GSK-3β P/T ratio. Shown are the phospho/total ratios of both control 
and DIO animals. 
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3.3.2.2 Effect on PKB/Akt protein 
3.3.2.2.1 Total PKB/Akt  
After 16 weeks on diet, PKB/Akt was significantly downregulated in untreated DIO 
animals as compared to untreated controls (**p= 0.0417). In addition, following four 
weeks of treatment with GSK-3 inhibitor, PKB/Akt was also significantly 
downregulated in treated DIOs when compared to treated control animals (##p= 
0.0026) (figure 3.50). Furthermore, total PKB/Akt was significantly downregulated in 
treated DIO animals as compared to untreated DIOs (#p= 0.0023). However, there 
was no significant difference in total PKB/Akt expression between treated and 
untreated control animals (figure 3.50). 
 
 
Figure 3.50: Total PKB/Akt. Shown is one of the Western blots representing total 
PKB/Akt expression, as well as a graph showing its fold stimulation (compared to the 
first loaded control that was assigned a value of 1) in controls and diet induced 
obese (DIO) animals. 
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3.3.2.2.2 Effect on PKB/Akt phosphorylation 
Following 16 week of diet, there was no significant difference in PKB/Akt 
phosphorylation between untreated DIOs and untreated control animals as well as 
when treated DIOs were compared to treated controls, following 4 weeks of 
treatment with the GSK-3 inhibitor (figure 3.51). However, PKB/Akt phosphorylation 
was significantly higher in treated DIOs than untreated DIO animals (#p= 0.0079), 
while there was no significant difference between treated and untreated control 
animals (figure 3.51). 
 
 
Figure 3.51: Phosphorylated PKB/Akt. Shown is the Western blot representing 
phosphorylated PKB/Akt, as well as a graph showing its fold stimulation (compared 
to the first loaded control that was assigned a value of 1) in controls and diet induced 
obese (DIO) animals. 
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3.3.2.2.3 Phospho/Total (P/T) ratio of PKB/Akt protein 
After 16 weeks of diet, there was no significant difference in P/T ratios when 
untreated DIOs and untreated control animals were compared. However, following 4 
weeks of treatment with GSK-3 inhibitor, P/T ratios of PKB/Akt were significantly 
higher in treated DIOs when compared with treated control animals (##p= 0.0174), as 
well as when treated DIOs were compared to untreated DIO animals (#p<0.0001) 
(figure 3.52). There was also no significant difference between treated and untreated 
control animals (figure 3.52). 
 
Figure 3.52: PKB/Akt (P/T ratio). Shown are the phospho/total ratios of both control 
and diet induced obese (DIO) animals. 
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3.3.2.3 Effect on total IRS-1 expression 
Following 16 weeks on diet, total IRS-1 expression was significantly downregulated 
in untreated DIOs when compared to untreated controls (**p= 0.0089) (figure 3.53). 
In addition, after four weeks of treatment with GSK-3 inhibitor, IRS-1 protein was 
also significantly downregulated in treated DIOs as compared to treated controls 
(##p= 0.0388) as well as when treated DIOs were compared to untreated DIO 
animals (#p= 0.0388). However, there was no significant difference between treated 
and untreated controls (figure 3.53). 
 
 
 
Figure 3.53: Total IRS-1 protein. Shown is the Western blot representing total IRS-1 
expression as well as a graph showing its fold stimulation (compared to the first 
loaded control that was assigned a value of 1) in controls and diet induced obese 
(DIO) animals. 
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3.3.2.4 Effect on total IRS-2 expression 
Following sixteen weeks of diet, the IRS-2 expression was significantly 
downregulated in untreated DIO animals as compared to untreated controls (**p= 
0.0220) (figure 3.54). However, after four weeks of treatment with GSK-3 inhibitor, 
there was no significant difference between treated DIOs and treated control 
animals. In addition, IRS-2 expression was significantly upregulated in treated DIOs 
when compared to untreated DIOs (#p= 0.0075) as well as in treated controls when 
compared to untreated controls (*p= 0.0040) (figure 3.54). 
 
 
 
Figure 3.54: Total IRS-2 protein. Shown is the Western blot representing total IRS-2 
expression as well as a graph showing its fold stimulation (compared to the first 
loaded control that was assigned a value of 1) in controls and diet induced obese 
(DIO) animals. 
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3.3.2.5 Effect on total SERCA-2a expression 
After 16 weeks on diet, SERCA-2a expression was significantly downregulated in 
untreated DIOs as compared to untreated controls (**p= 0.0269) (figure 3.55). 
However, following four weeks of treatment with GSK-3 inhibitor, there was no 
significant difference in total SERCA-2a expression when treated DIO animals and 
treated controls were compared. In addition, there was also no significant difference 
between treated and untreated DIOs as well as when treated and untreated control 
animals were compared (figure 3.55). 
 
 
 
Figure 3.55: Total SERCA-2a protein. Shown is the Western blot representing total 
SERCA-2a expression as well as a graph showing its fold stimulation (compared to 
the first loaded control that was assigned a value of 1) in controls and diet induced 
obese (DIO) animals. 
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3.3.2.6 Effect on PLM protein 
3.3.2.6.1 Total PLM protein 
Following 16 weeks on diet, total PLM expression was significantly upregulated in 
untreated DIOs as compared to untreated control animals (**p= 0.0027). In addition, 
after four weeks of treatment with GSK-3 inhibitor, total PLM expression was also 
significantly upregulated in treated DIOs when compared to treated controls (figure 
3.56). However, there were no significant differences in total PLM expression 
between treated and untreated DIOs as well as when treated and untreated control 
animals were compared (figure 3.56).  
 
 
 
Figure 3.56: Total PLM. Shown is the Western blot representing total PLM 
expression as well as a graph showing its fold stimulation (compared to the first 
loaded control that was assigned a value of 1) in controls and diet induced obese 
(DIO) animals. 
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3.3.2.6.2 Effect on phospholamban (PLM) phosphorylation 
Following 16 weeks on diet, PLM phosphorylation was lesser in untreated DIOs than 
untreated control animals (**p= 0.0177). However, after four weeks of treatment with 
GSK-3 inhibitor, there was no significant difference in phosphorylated PLM protein 
when treated DIOs and treated control animals were compared (figure 3.57). PLM 
phosphorylation was significantly higher in treated DIOs than untreated DIO animals 
(#p= 0.0249). There was no significant difference in phosphorylated PLM when 
treated and untreated control animals were compared (figure 3.57).  
 
 
 
Figure 3.57: Phosphorylated PLM. Shown is the western blot representing 
phosphorylation of PLM protein as well as a graph showing its fold stimulation 
(compared to the first loaded control that was assigned a value of 1) in both treated 
(Tr) and untreated (Untr) animals. 
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3.3.2.6.3 Phospho/Total (P/T) ratio of PLM protein 
The P/T ratios of PLM were significantly lower in untreated DIO animals than 
untreated controls (**p= 0.0005) as well as in treated DIOs when compared to 
treated control animals (##p= 0.0118) (figure 3.58). However, there was no significant 
difference in P/T ratios of PLM when treated and untreated DIO animals are 
compared. In addition, there was also no significant difference between treated and 
untreated controls (figure 3.58). 
 
Figure 3.58: Phospho/Total ratio of PLM. Shown are the Phospho/Total ratios of 
PLM in both treated and untreated DIO and control animals. 
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3.3.3 Effect on Calcium ATPase activity 
Following 16 weeks on diet, calcium ATPase activity was significantly lower in 
untreated DIOs when compared to untreated controls (**p= 0.0007). In addition, after 
four weeks of treatment with GSK-3 inhibitor, calcium ATPase activity was still lower 
in treated DIO animals as compared to treated controls (##p= 0.0296) (figure 3.59). 
However, there was no significant difference in calcium ATPase activity when 
comparing treated and untreated DIOs as well as when treated and untreated control 
animals were compared (figure 3.59).  
 
 
Figure 3.59: Calcium ATPase activity. Shown are the activities of both treated and 
untreated controls and DIO animals as determined by the amount of inorganic 
phosphate (Pi) produced. 
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CHAPTER 4 
DISCUSSION AND CONCLUSION 
4.1 Discussion 
The primary aim of the current study was to determine the role of GSK-3 protein in 
the development of cardiomyopathy associated with obesity and insulin resistance. It 
has been well established that obesity plays a role in myocardial dysfunction (Poirier 
et al. 2005). The poor myocardial function in obesity has been attributed to metabolic 
abnormalities such as dyslipidemia, glucose intolerance, insulin resistance and is 
associated with impaired myocardial Ca2+ handling (Lopaschuk et al. 2007, Chess 
and Stanley 2008).  
 
The current study focused on changes in DIO animals that may affect myocardial 
contractility. To achieve the aims of the present study, the well characterized rat 
model of diet induced obesity (DIO) was used to determine whether GSK-3 and its 
substrate proteins (IRS-1, IRS-2, PKB/Akt, SERCA-2a and PLM) are dysregulated. 
We first characterized GSK-3 and its substrate proteins at 8 weeks to determine 
early effects especially on SERCA-2a expression. We then again determined 
whether GSK-3 or its down-stream substrates are dysregulated at 16 weeks. The 8 
and 16 weeks time points were both considered as baseline, in order to, after the 
treatment with a GSK-3 inhibitor, determine whether GSK-3 plays a role in the 
observed changes and whether these changes may be reversible. 
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4.1.1 Animal model (Biometric parameters) 
The animal model was developed by feeding the animals with a rat chow diet 
supplemented with sucrose and condensed milk, while control animals were fed a 
normal rat chow diet for a period of 8 or 16 weeks. Thus DIO animals consumed 
more energy per day than the controls. It has been well established that a long term 
positive imbalance between energy intake and expenditure results in obesity and 
insulin resistance (review by Sethi and Vidal Puig 2007). In addition, a high sucrose 
containing diet administered to animals have been associated with a variety of 
effects including obesity, insulin resistance, hyperinsulinaemia and hyperglycaemia 
depending on the model (Reaven et al. 1979; Soria et al. 2001; Fukuchi et al. 2004, 
Kamgang et al. 2005). In the current study, at both 8 (figure 3.1-2) and 16 (figure 
3.14-15) weeks, DIO animals were significantly bigger than the control animals and 
had increased intra-peritoneal fat depots. This indicates that the DIO animals were 
indeed abdominally obese and possibly insulin resistant. Insulin resistance was not 
measured at this time point; however, it was measured in both treated and untreated 
animals following treatment with GSK-3 inhibitor (section 4.1.3.3). 
 
4.1.2 Expression and phosphorylation of proteins at baseline (8 and 16 weeks) 
4.1.2.1 8 weeks time point 
Following 8 weeks on diet, there was no significant difference in expression and 
basal phosphorylation of GSK-3 (figure 3.3-7), PKB/Akt (figure 3.8-10) and total IRS-
2 (figure 3.12) proteins. GSK-3 protein has been shown to be elevated in tissues of 
insulin resistant obese rodent models of type 2 diabetes (review by Henriksen and 
Dokken 2006). However, total IRS-1 expression was significantly downregulated in 
DIO animals as compared to the age matched controls (figure 3.11). 
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We conclude that these animals are insulin resistant after only 8 weeks on diet, as 
the upstream located IRS-1 protein is downregulated four fold. Insulin binds to its 
receptor and stimulates IRS-1 protein, the activated IRS-1 protein then activates 
PKB/Akt via PI3K pathway (White 2002). In the present study, the downregulated 
IRS-1 protein may therefore impair activation of PKB/Akt protein, thus GSK-3 which 
is normally inhibited by PKB/Akt protein remains active. In addition, Kim et al. 1999 
and Storgaard et al. 2001, also observed in skeletal muscle of type 2 diabetes 
mellitus patients and subjects with impaired glucose tolerance, insulin induced 
defects in IRS and PI3K expression but normal PKB/Akt activation. As the IRS-1 
protein is downregulated, we thought that there may be other mechanisms or 
proteins that may take over the significant role of IRS-1. So we investigated the IRS-
2 protein and we found that there was no significant difference in total IRS-2 
expression between controls and DIO animals. It is therefore possible that IRS-2 
may compensate for IRS-1 at this stage. The effect of insulin stimulation on this 
pathway has not been measured. 
 
GSK-3 is known to control the expression of SERCA-2a protein (Michael et al. 2004), 
therefore we determined the total SERCA-2a expression. We found that total 
SERCA-2a expression was significantly downregulated by approximately 50% in 
hearts from DIO animals as compared to those coming from the control animals 
(figure 3.13). Although, SERCA-2a expression was down regulated in DIO animals, it 
was not associated with increased GSK-3 expression at this early stage, as was 
reported in previous studies (Michael et al. 2004). 
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4.1.2.2 16 weeks time point 
Following 16 weeks of diet, there was still no significant difference in total GSK-3 
protein (figure 3.16) as well as its basal phosphorylation (figure 3.17-20) between 
DIOs and the age matched control animals. Although there was no significant 
difference in total GSK-3 protein, there was a strong trend to elevated expression in 
DIO animals. Total PKB/Akt expression was significantly downregulated in DIO 
animals while there was no significant difference in its basal phosphorylation 
between control and DIO animals (figure 3.21-23). After 16 weeks of diet, DIO 
animals presented with decreased IRS-1 (figure 3.24) and IRS-2 (figure 3.25) protein 
expression. However, the PI3K associated activity of IRS-1/2 was not measured in 
the current study.  
 
Previous studies, have reported that GSK-3 protein phosphorylates IRS-1 on a 
serine residue thus making it a poorer substrate for tyrosine phosphorylation by the 
insulin receptor thereby attenuating insulin signaling (Eldar-Finkelman and Krebs 
1997). In addition, in studies in which PI3K activity associated to IRS-1 or IRS-2 
have been performed side by side, a decrease in both IRS-1 and IRS-2 associated 
insulin stimulated PI3K activity has been observed in muscle biopsies from obese 
type 2 diabetic patients (Kim et al. 1999; Vollenweider et al. 2002; Bouzakri et al. 
2003). Our observations therefore corroborate the observations of faulty signaling on 
the level of IRS in obesity and insulin resistance. 
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In type 2 diabetes mellitus, the first change in cardiac functioning is diastolic 
dysfunction (Cosson and Kevorkian 2003; Fang et al 2003). It has been shown that 
this dysfunction is induced by a decreased Ca2+ uptake by the myocardial 
sarcoplasmic reticulum as well as myocardial interstitial fibrosis (Dutta et al. 2002; 
Wold et al. 2005; Van Hoeven and Factor 1990). SERCA-2a plays a role in the Ca2+ 
uptake by the sarcoplasmic reticulum (Takeda 2010).  
 
In the current study we therefore evaluated the expression and activity of the 
SERCA-2a protein. We found that the expression of SERCA-2a protein was 
significantly downregulated in DIO animals as compared to the age matched controls 
(figure 3.26). It has been reported that GSK-3 protein down regulates the expression 
of SERCA-2a by acting directly on its promoter (Michael et al. 2004). In our model, 
this early decreased SERCA-2a expression may have been caused by a different 
mechanism other than the actions of GSK-3. It has been well established that 
corticosteroids also decrease mRNA levels of SERCA-2a protein, while it increase 
mRNA levels of SLN (Gayan-Ramirez et al. 2000). However, the levels of 
corticosteroids were not measured in the current study.  
 
In addition, it has been shown that the expression of SERCA-2a and PLM in the 
myocardium is dependent on the circulating concentration of tri-iodothyronin (T3) 
hormone (Nagai et al. 1989; Zarain-Herzberg et al. 1994; Holt et al. 1999). It has 
been well established that hyperthyroidism promotes an up regulation of SERCA-1a 
and down-regulation of SERCA-2a in red muscles of rodent animals (Nunes et al. 
1985; Muller et al. 1994; Simonides et al. 2001; Arruda et al. 2003; Yamada et al. 
2004). Arruda et al. 2005, using hyperthyroid rabbit skeletal muscle showed that the 
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Western blot analysis indicates a 6 fold increase in SERCA-1a expression and a 
50% decrease in SERCA-2a expression. In the current study, the levels of thyroid 
hormone were not measured, so it may have also played a role in SERCA-2a down 
regulation. 
 
The activity of SERCA-2a is negatively regulated by PLM protein (Tada et al. 1974; 
Munch et al. 2000). Thus we also investigated the expression of PLM and we found 
that hearts from DIO animals had significantly increased total PLM expression while 
its phosphorylation was decreased (figure 3.27-29). Our results therefore showed 
that PLM protein was upregulated and more active in DIO animals. Thus SERCA-2a 
was also affected by changes in PLM expression and phosphorylation. An 
unidentified mechanism may have decreased the content of SERCA-2a in the 
cardiac muscle cell, at the same time PLM may have decreased its activity. To 
further confirm this, we investigated the activity of the SERCA-2a protein, and we 
found that the SERCA-2a activity was significantly lower in DIO animals as 
compared to the controls (figure 3.30). The lower SERCA-2a activity in DIO animals 
was associated with the decreased SERCA-2a expression and increased total PLM 
expression. It has been previously shown that, the SERCA-2a activity is under 
inhibitory control of PLM (James et al. 1989; Kimura et al. 1996), while 
phosphorylation of PLM reactivates it (Tada et al. 1975). 
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Using the in vivo perfused isolated hearts, we investigated the contractile ability of 
hearts from both DIO and control animals and their ability to with stand low flow 
ischemia. In the current study, hearts were stabilized for 30 minutes, subjected to 
low flow ischemia (0.2 ml/min) for 25 minutes followed by 30 minutes of reperfusion. 
We monitored their contractility during and after low flow ischemia to give an 
indication of contractile ability and the recovery of contraction. We found no 
significant difference in systolic pressure (figure 3.31), diastolic pressure (figure 
3.32), LVDevP (figure 3.33), PCDP (figure 3.37B), EIDP (figure 3.37C), TPC (figure 
3.37A) and the rate of coronary flow (figure 3.38) when DIO and control animals 
were compared. The heart rate (figure 3.34) and rate pressure product (figure 3.35) 
were significantly lower in DIO animals than the age matched controls at baseline. 
However, there was no significant difference at reperfusion. 
 
Results indicated that the RPP of DIO animals was lower than control animals at 
baseline, however, there was no significant difference after low flow ischemia. In 
addition, during low flow ischemia, DIO animals had a longer time to onset of 
ischemic contracture than control animals (figure 3.36). This was quite surprising, as 
the SERCA-2a expression was downregulated in these DIO animals, one would 
expect poor recovery in DIO animals. In addition, several studies conducted on 
animal models of heart failure and human failing hearts, suggested that alterations in 
SR Ca2+ handling are a critical feature of the hypertrophied or failing myocardium 
(review by Periasamy and Huke 2001). However, there is some contrasting evidence 
that state that life may be possible without SERCA-2a (review by Trafford et al. 
2009). In addition, Andersson et al. 2009, using a novel inducible knockout of the 
SERCA-2 gene in adult mice, has shown that the hearts from these mice can 
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function in the near complete absence of SERCA-2. They discovered that despite a 
rapid decline in SERCA-2 protein levels to less than 5% of the control and a 
reduction of SR Ca2+ content by ~80%, the cardiac function is only modestly reduced 
(Andersson et al. 2009). In the current study, the retained contractile ability of hearts 
from DIO animals may be due to cardiac adaptive capacity. In addition, in the current 
study we only measured SERCA-2a expression and not SERCA-1a, other isorforms 
or the ryanodine receptor. However, it has been suggested that SERCA-1a does not 
only compete with SERCA-2a for functional site in the SR, it may also play a 
compensatory role when SERCA-2a isoform is downregulated (review by Periasamy 
and Huke 2001). 
 
4.1.3 16 weeks plus treatment with GSK-3 inhibitor 
GSK-3 protein was first discovered as a regulator of glycogen synthase thus playing 
a role in glycogen synthesis (Embi et al. 1980). However, abnormally high activities 
of GSK-3 protein has been implicated in several pathological disorders which include 
type 2 diabetes, neuron degenerative and affective disorders (Eldar-Finkelman et al. 
2010). This led to the development of new generations of inhibitors with specific 
clinical implications to treat diseases such as type 2 diabetes, Alzheimer‘s disease 
and mood disorders (Martinez 2008). However, there is currently no clinical data 
available on long term GSK-3 inhibition, while preclinical data strongly support its 
important future role (review by Huisamen and Lochner 2010). In addition, there is 
very little data available on heart research (review by Huisamen and Lochner 2010). 
In the current study we treated the animals with the specific GSK-3 inhibitor that 
target the ATP binding site, in order to determine whether GSK-3 protein plays a role 
in changes observed at 8 and 16 weeks time points (baseline) and whether these 
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changes may be reversible. We investigated its effect on body weight, IP fat, 
ventricular weight, tibia length, fasting blood glucose, plasma insulin levels, protein 
expression and phosphorylation, as well as Calcium ATPase activity. 
 
4.1.3.1 Effect of the inhibitor on body weight (BW) and IP fat mass 
In the current study, we found that the DIO animals were significantly bigger than the 
controls (figure 3.39). This increased body mass was positively associated with 
increased intra-peritoneal fat mass (figure 3.40). However, when comparing treated 
and untreated groups, we found that treated controls were significantly bigger than 
untreated controls while treated DIO animals were significantly smaller than 
untreated DIOs (figure 3.39). Both treated and untreated DIO animals had increased 
IP fat as compared to treated and untreated control animals (figure 3.40). However, 
there was no significant difference in IP fat when treated and untreated DIOs were 
compared as well as between treated and untreated control animals (figure 3.40). As 
compared to the baseline results, treatment decreased the body weight of DIOs 
while it significantly increased the body weight of control animals. There should be 
other mechanisms triggered that may lead to a decreased body weight in DIO 
animals, that do not take place in control animals. 
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4.1.3.2 Effect of the inhibitor on ventricular weight (VW) and Tibia length (TL) 
4.1.3.2.1 Effect on ventricular weight 
Cardiac remodelling is one of the detrimental features associated with obesity (Abel 
et al. 2008, Chess and Stanley 2008). It has been reported that obesity may 
predispose the individual to fatal ventricular arrhythmias by inducing cardiac 
hypertrophy, which is an arrhythmogenic risk factor (Wolk 2000). In the current 
study, the ventricular weight was also measured to determine if the hearts were 
hypertrophied or not. We found that ventricles from DIO animals were significantly 
bigger than ventricles from control animals in both treated and untreated groups 
(figure 3.41). In addition, we found that ventricles from treated control animals were 
significantly bigger, while treated DIO animals had significantly smaller ventricles 
(figure 3.41). As the same results were observed in body weight, ventricular weight 
was positively associated with the body weight and this may indicate hypertrophy in 
hearts from DIO animals. This might be because the ventricles need to compensate 
for the higher volumetric load in the larger animals. 
 
4.1.3.2.2 Effect on tibia length 
Because body weight vs ventricular weight may cause false positive values for 
hypertrophy in DIO animals, as the ventricular weight may correlate with body 
weight. The tibia length was measured and we found no significant difference in tibia 
length in both treated and untreated animals (figure 3.42). Both diet and treatment 
did not have an influence in tibia length. Although there was no significant difference 
in tibia length, VW/TL ratio was significantly higher in untreated DIO as compared to 
untreated controls, an indication of hypertrophy in DIO animals. Hypertrophy in 
untreated DIOs may be due to a compensatory response as they have reduced 
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SERCA-2a activity. However, following the treatment with GSK-3 inhibitor, the 
VW/TL ratio was significantly higher in treated controls, while it was significantly 
lower in treated DIO animals (figure 3.43).  
 
Therefore, inhibition of GSK-3 in a normal animal may lead to development of 
hypertrophy, while inhibition of GSK-3 activity in DIO animals did not exacerbate this 
hypertrophy. Haq et al. 2000 using lithium chloride (LiCl), also demonstrated that 
inhibition of GSK-3 activity leads to features of cardiac hypertrophy. In DIO animals, 
treatment with GSK-3 inhibitor improved or reversed cardiac hypertrophy. Recent 
evidence shows that GSK-3 functions as a negative regulator of cardiac hypertrophy 
(Haq et al. 2000; Badorff et al. 2002). In addition, it has been shown that insulin 
induced phosphorylation and inactivation of GSK-3 is impaired in diabetes and 
insulin resistance (Hardt and Sadoshima 2002). So this may not only contribute to 
impaired glycogen synthesis but also to enhanced protein synthesis, leading to the 
development of diabetic cardiomyopathy (Laviola et al. 2001).. 
 
4.1.3.3 Effect of the inhibitor on fasting blood glucose and insulin levels 
Among other functions of GSK-3 protein, it is well known to phosphorylate and 
inactivate glycogen synthase, a rate limiting enzyme of glycogenesis, thus playing a 
role in blood glucose homeostasis (Parker et al. 1983, Roach 1990, Zhang et al. 
1993). It has been well established that one of the major features of type II diabetes 
mellitus is the impairment of both basal and insulin stimulated glucose metabolism in 
peripheral tissues (Patel et al. 2004). In addition, it has been shown that the muscle 
tissue from type II diabetic patients has reduced glycogen deposition as compared to 
normal tissues, which is correlated with decreased glycogen synthase activity, 
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increased GSK-3 activity and impaired insulin responsiveness (Shulman et al. 1990, 
Cline et al. 1994). In the current study, animals were treated with specific GSK-3 
inhibitor and the fasting blood glucose and plasma insulin levels were measured to 
determine if the inhibitor improved them. As expected, we found that the untreated 
DIO animals had significantly higher fasting blood glucose levels (figure 3.44), an 
indication of pre-diabetic state. These animals were not diabetic, as the cut off point 
indicating diabetes is 8 Mmol/L. Although, the treatment with GSK-3 inhibitor had no 
effect on fasting blood glucose levels, the significant difference measured in 
untreated groups was not seen after treatment (figure 3.44).  
 
A variety of chemically distinct selective and specific GSK-3 inhibitors have also 
been shown to improve insulin action both in vivo in animal models of insulin 
resistance (Cline et al. 2002; Henriksen and Dokken 2006) and in vitro in tissues and 
cultured cells (Ring et al. 2003; Coghlan et al. 2000; Nikoulina et al. 2002). For that 
reason, fasting plasma insulin levels were also measured and we found that the 
untreated DIO animals had significantly higher levels of insulin, indicating insulin 
resistance in these animals (figure 3.45). These higher insulin and glucose levels in 
untreated DIO animals showed that the experimental animals were indeed pre-
diabetic and insulin resistant. Following the treatment with the GSK-3 inhibitor, the 
insulin levels were still significantly higher in DIO animals, showing that the treatment 
could not improve whole-body insulin resistance. This is underscored by the 
unchanged HOMA insulin resistant (IR) index (figure 3.46). 
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In the current study, the diet influenced both plasma glucose and insulin levels, while 
treatment had no effect. However, previous in vitro studies of cultured human 
skeletal muscle chronically treated with GSK-3 inhibitors (CHIR98014 and 
CHIR98023), have shown a significant increase in both basal and insulin stimulated 
glucose uptake (Nikoulina et al. 2000). In the current study, this was not supported. 
This might be because of the difference between in vitro and in vivo treatment with 
the inhibitor. However, amongst other studies, Ciaraldi et al. 2010, also showed that 
a reduction in GSK-3β expression had no statistical significant effect on basal 
glucose uptake in muscle cells. However, only a modest increase glucose uptake 
was observed when control cells were exposed to acute insulin stimulation (Ciaraldi 
et al. 2010). In addition, Henriksen and Teachey, 2007 also reported that, in the 
absence of insulin, no effects of GSK-3 inhibition were detected on glucose 
transport. 
 
4.1.3.4 Effect of the inhibitor on protein expression and phosphorylation 
4.1.3.4.1 Effect on GSK-3 expression and phosphorylation 
In order to inhibit a specific protein kinase with a drug, the drug should either 
decrease its expression, modulate its phosphorylation, or compete for substrate or 
the ATP binding site (Van Wauwe and Haefner 2003). In the current study, following 
the treatment with GSK-3 inhibitor, we found no significant difference in total GSK-3 
expression in both treated and untreated animals (figure 3.47). As mentioned earlier, 
one of the mechanisms of inhibiting this protein is to increase its phosphorylation. 
We also investigated GSK-3 phosphorylation and we found that GSK-3 
phosphorylation was significantly increased in treated controls, while there was no 
significant difference in treated DIO animals (figure 3.48-9). However, a trend 
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towards increased GSK-3 phosphorylation was observed in treated DIO animals 
(figure 3.48-9). This increase in phosphorylation of GSK-3 in treated control animals 
may play a role in the activity of the protein. 
 
Since the GSK-3 inhibitor used in this study competes for the ATP binding site; there 
may not be a decrease in total GSK-3 expression. However, besides competing for 
the ATP biding site, we showed that in control animals the treatment inhibited GSK-3 
through phosphorylation, we also speculate that the increased tendency observed in 
treated DIO animals may have been just enough to inhibit the GSK-3 protein. In 
addition, other studies using GSK-3 inhibitor 4-benzyl-2-methyl-1, 2, 4-
thiadiazolidine-3, 5-dione (TDZD-8) have shown increased GSK-3 serine-9 
phosphorylation consistent with inactivation of the kinase (Gao et al. 2008). 
However, the other way to measure the extent of GSK-3 inhibition is to measure the 
activity of glycogen synthase (GS) as GSK-3 directly regulates its activity (MacAulay 
et al. 2005). The activity of GS was not measured in the current study.  
 
4.1.3.4.2 Effect on PKB/Akt, IRS-1 and IRS-2 proteins 
4.1.3.4.2.1 Effect on PKB/Akt expression and phosphorylation 
In insulin sensitive cells, insulin binds to its receptor and activates IRS-1 or IRS-2 
protein which then stimulates PKB/Akt via PI3K pathway (Saltiel and Pessin 2003; 
Shepherd 2005 ). The activated PKB/Akt protein is known to directly phosphorylate 
GSK-3 protein on its serine residue thus inhibiting it (Lawrence and Roach 1997). It 
has also been shown that in vivo, PKB/Akt does not only regulate GSK-3 activity but 
also directly interact with GSK-3 as both proteins can be co-immunoprecipitated (van 
Weeren et al. 1998). Since GSK-3 and PKB/Akt can interact with each other, we 
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investigated the effect of GSK-3 inhibition on expression and phosphorylation of 
PKB/Akt protein.  
 
We found that total PKB/Akt was significantly down regulated in untreated DIO 
animals as compared to untreated controls (figure 3.50). Treatment with GSK-3 
inhibitor decreased total PKB/Akt even further in treated DIO animals (figure 3.50). In 
addition, the treatment significantly increased PKB/Akt phosphorylation in DIO 
animals but had no effect in control animals (figure 3.51-2). This and the elevated 
P/T ratio indicate that PKB/Akt was more active in treated DIO animals, thus possibly 
contributing to the inhibition of GSK-3 activity. It may also reflect the higher level of 
IRS-2 expression. In contrast to the observed changes, Nikoulina et al. 2001, 
reported that following the treatment with GSK-3 inhibitor, PKB/Akt expression was 
unaltered indicating the specificity of the inhibitor. This might also be model specific 
as Nikoulina et al. 2001, worked in skeletal muscle cell cultures taken from patients. 
 
4.1.3.4.2.2 Effect on IRS-1 expression 
It has been shown that the treatment of muscle cell cultures from type II diabetic 
human subjects with a GSK-3 inhibitor (Chiron) increases the expression of IRS-1 
protein, suggesting that GSK-3 may participate in the post-transcriptional regulation 
of insulin signaling components (Nikoulina et al. 2002). In the current study, we 
found that the total IRS-1 expression was significantly downregulated in untreated 
DIO animals (figure 3.53). However, the treatment with GSK-3 inhibitor decreased 
total IRS-1 expression further in DIO animals while it had no effect in control animals 
(figure 3.53).  
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We conclude that GSK-3 was not involved in down regulation of IRS-1 protein in our 
model. Instead GSK-3 inhibition further lowered IRS-1 expression. However, it was 
reported that GSK-3 phosphorylates IRS-1 on a serine residue and inhibits its activity 
(Eldar-Finkelman and Krebs 1997), (which was not measured in the current study), 
having no effect on its expression. In addition, Ciaraldi et al. 2010, also reported that 
IRS-1 expression was unaltered in skeletal muscle cell culture, following knock down 
of GSK-3β. However, in contrast to that, it has been reported that the longer term 
exposure of human muscle cell cultures to the GSK-3 inhibitor is associated with 
upregulation of IRS-1 and downregulation of GSK-3 protein expression (Nikoulina et 
al. 2002). 
 
4.1.3.4.2.3 Effect on IRS-2 expression 
Since IRS-1 expression was still depressed in DIO animals, the effect on IRS-2 
expression was investigated. We found that untreated DIO animals had decreased 
IRS-2 expression (figure 3.54). However, following the treatment with GSK-3 
inhibitor, IRS-2 expression was significantly upregulated in both treated DIOs and 
control animals (figure 3.54). This indicates that the treatment with the GSK-3 
inhibitor significantly increased IRS-2 expression in both control and DIO animals 
while it had no effect on IRS-1 expression. Our results show that GSK-3 protein may 
act as a regulator of IRS-2 expression. In support to that, Nikoulina et al. 2002, 
suggested that GSK-3 may participate in the post-transcriptional regulation of insulin 
signaling components. The results also show that IRS-2 may compensate for 
reduced IRS-1 activity in DIO animals. 
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4.1.3.4.3 Effect on SERCA-2a and PLM proteins 
4.1.3.4.3.1 Effect on SERCA-2a expression 
In heart, GSK-3 plays several important roles such as in negative regulation of 
hypertrophy. On the other hand, its inhibition during ischemia and reperfusion (I/R) 
has been implicated as cardioprotective (Omar et al. 2010). Furthermore, GSK-3 
protein has also been shown to play a role in myocardial contractility by directly 
down regulating the expression of SERCA-2a thereby leading to an inability to 
normalize cytosolic Ca2+ in diastole (Michael et al. 2004). SERCA-2a plays an 
important role in the uptake of calcium from the cytosol back to the SR during 
myocardial relaxation, thus it is considered as a primary regulator of the Ca2+ levels 
and myocardial contractility (Schimdt et al. 2001). However, it has been shown that 
SERCA-2a expression is down regulated in diabetic and insulin resistant rodents 
(Pearce et al. 2004 and Michael et al. 2004).  
 
In the current study, the animals were treated with the GSK-3 inhibitor to investigate 
whether SERCA-2a expression and activity will be improved after the treatment. We 
found that SERCA-2a expression was significantly downregulated in untreated DIO 
animals (figure 3.55). Following treatment with the GSK-3 inhibitor, SERCA-2a 
expression was unchanged in DIO animals (figure 3.55). However, there was a 
tendency towards an increase in SERCA-2a levels in treated DIOs as compared to 
untreated DIO animals. From the negative results of the inhibitor on SERCA-2a 
expression, we conclude that other unidentified role players are possibly involved in 
regulation of SERCA-2a expression in this model. It is also possible that the exact 
mix of protective kinases required for protection is model and species dependent 
(Murphy and Steenbergen 2008). 
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In contrast to the results found in the current study, previous studies such as those of 
Michael et al. 2004 using transgenic mice, showed that the gene transfer of GSK-
3β(SA9) containing a Ser-9 to Ala mutation that prevents inactivation of GSK-3β by 
serine-9 phosphorylation thus increasing GSK-3 activity, significantly reduced the 
expression of SERCA-2a protein. They then inhibited GSK-3β with Lithium Chloride 
(LiCl), to determine whether the inhibition of SERCA-2a expression was reversible or 
not. They showed that LiCl completely reversed the inhibition of SERCA-2a mRNA 
expression by GSK-3β (SA9) (Michael et al. 2004). LiCl however, is not a specific 
drug. 
 
4.1.3.4.3 Effect on PLM expression and phosphorylation 
In the current study, we also investigated the effect of GSK-3 inhibition on 
expression of PLM protein, which is known to regulate the activity of SERCA-2a 
(James et al. 1989; Asahi et al. 2003). We found that the expression of PLM protein 
was significantly upregulated in untreated DIO animals (figure 3.56). Following the 
treatment with the GSK-3 inhibitor, PLM expression was still upregulated to the same 
extent in DIO animals, therefore the treatment had no effect on PLM expression 
(figure 3.56). In addition, PLM phosphorylation was significantly decreased in 
untreated DIO animals (figure 3.57). However, the treatment with GSK-3 inhibitor 
significantly increased the phosphorylation of PLM protein in treated DIOs while it 
had no effect in control animals (figure 3.57-8). Although PLM expression was 
upregulated in DIO animals the treatment increased its phosphorylation thus 
rendering it less active. To the best of our knowledge, there are very few studies 
reporting changes in PLM expression following treatment with the GSK-3 inhibitor. 
Michael et al. 2004, using GSK-3β transgenic mice, showed that the expression of 
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PLM was unaltered in GSK-3β transgenic mice and its serine-16 phosphorylation 
was only modestly reduced. From the change in PLM phosphorylation, we expected 
an improvement in the SR Ca2+-ATPase activity. 
 
4.1.3.5 Effect on calcium ATPase activity (SERCA-2a activity) 
It has been well established that SERCA-2a activity is positively associated with 
increased SERCA-2a expression and decreased PLM expression or increased PLM 
phosphorylation (Vittorini et al. 2007). In the present study, following the treatment 
with GSK-3 inhibitor, we measured the calcium ATPase activity. We found that the 
calcium ATPase activity was significantly decreased in untreated DIO animals (figure 
3.59). Treatment with the GSK-3 inhibitor had no effect on calcium ATPase activity 
(figure 3.59). However, there was a trend towards an increase in SERCA-2a activity 
in treated DIO animals. In addition, the phosphorylation of PLM was increased 
almost 2 fold in DIO animals, so SERCA-2a activity may have increased in vivo, 
because we only used isolated SR membranes therefore the regulation by PLM was 
probably absent. Previous studies showed that GSK-3 inhibition reduced both 
diastolic and systolic Ca2+ overload, an indication of increased SERCA-2a activity, 
and this has been proposed as a strategy to improve post ischemic cardiomyocyte 
survival following ischemia and reperfusion, thus playing a role in cardioprotection 
(Murphy and Steenbergen 2005; Omar et al. 2010).  
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4.2 Conclusion 
Our original hypothesis was that, GSK-3 protein and its substrate proteins play a role 
in the development of cardiomyopathy associated with obesity and insulin 
resistance. We wanted to determine whether GSK-3 and its substrate proteins are 
dysregulated in obese and insulin resistant animals. In the current study, we first 
showed that yes, indeed, the consumption of high calorie diet as well as an 
imbalance between energy intake and expenditure lead to increased body weight 
(obesity), and insulin resistance in male Wistar rats. This lead to the disruption of 
insulin signaling pathway, characterized by alterations in proteins involved such as 
IRS-1, IRS-2, PKB/Akt and GSK-3 at baseline. However, GSK-3 inhibition improved 
IRS-2 expression while it had no effect on IRS-1. So we conclude that GSK-3 may 
play a role in regulation of IRS-2 expression but not in IRS-1. However, IRS-2 may 
compensate for IRS-1 activity. In addition, GSK-3 inhibition also increased PKB/Akt 
phosphorylation. We showed that DIO animals developed cardiac hypertrophy at 16 
weeks. However, we showed that GSK-3 inhibition may reverse cardiac hypertrophy 
in DIO animals, thus acting as a negative regulator of hypertrophy, although it 
exarcerbated development of hypertrophy in control animals. 
 
We also showed that SERCA-2a was significantly downregulated while its regulatory 
protein PLM was upregulated in DIO animals indicating that these animals 
developed cardiomyopathy as early as 8 weeks on diet. The increased tendency of 
GSK-3 at both 8 and 16 weeks may have played a role in down regulation of 
SERCA-2a expression. However, there was no change in SERCA-2a expression 
after the treatment with the GSK-3 inhibitor, so we cannot conclude whether GSK-3 
protein played a role in observed changes. However, the tendency towards increase 
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in SERCA-2a expression and increased PLM phosphorylation in treated DIO animals 
is promising. As we did not conclusively showed that the GSK-3 inhibitor, at the dose 
prescribed by the pharmaceutical company and with an oral administration route, 
was 100% effective to actually inhibit GSK-3 activity, further studies need to be 
conducted. 
 
4.3 Limitations of this study 
In the current study, only male Wistar rats were used. These animals were only fed a 
high calorie diet. The current study only focused on the insulin signaling pathway, 
especially on GSK-3 protein. There may be other pathways involved in the regulation 
of SERCA-2a as well as in the development of cardiomyopathy. Inhibition of 
downstream substrates of GSK-3 needs to be demonstrated conclusively. 
Unfortunately, a limited amount of inhibitor for in vivo studies was supplied. 
 
4.4 Future studies 
To confirm the effectiveness of the inhibitor in vivo, we will investigate the expression 
and phosphorylation of glycogen synthase protein. Glycogen synthase is a 
downstream substrate of GSK-3, which plays a role in regulation of glycogen 
synthesis (MacAulay et al. 2005). We expect to find decreased insulin stimulated 
phosphorylation. We would also like to investigate the effect of the GSK-3 protein on 
myocardial contractility using low flow ischemia and reperfusion. In addition, we 
would like to directly treat the hearts from DIO and control animals with GSK-3 
inhibitor just before low flow ischemia. We will then carefully monitor these hearts 
during ischemia and at reperfusion to see if there are any changes as compared to 
untreated hearts. 
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